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Background: Endometrial carcinoma is the most common pelvic malignancy in the 
Western world and the incidence is increasing. Endometrial carcinomas are surgically 
staged according to FIGO 2009 criteria, and the lack of robust preoperative staging 
methods results in overtreatment of this patient population, mostly by unnecessary 
invasive surgery and lymphadenectomy in patients with localized disease. New 
imaging methods are highly warranted to aid more accurate preoperative staging and 
thus potentially reduce unwanted post-operative side effects, decrease the amount of 
unnecessary resource-demanding surgery and to provide better individualized therapy 
for this patient group. 
Aims: Promote individualized treatment, reduce morbidity and facilitate 
implementation of targeted therapy among endometrial carcinoma patients by 
investigating functional and structural imaging biomarkers in pre-operatively acquired 
MRI and FDG-PET/CT. 
Methods: All patients with histologically confirmed endometrial carcinoma at 
Haukeland University Hospital were consecutively referred to pre-operative MRI 
and/or FDG-PET/CT for a period of four years. Images were individually read by two 
to four radiologists and nuclear medicine physicians conducting staging and image 
quantifications in a standard imaging report. Results were compared to the results of 
surgical staging regarding the tumors depth of myometrial invasion, cervical stromal 
involvement and the presence of lymph node metastases, these three criteria being 
well-established parameters predicting aggressiveness of disease and survival in 
endometrial cancer. 
Main Results: The evaluation of the staging criteria depth of myometrial invasion, 
cervical stromal involvement and the presence of lymph node metastases on pre-
operative 1.5T MRI are prone to considerable inter-observer variability (κ=0.4, 0.5 and 
0.6, respectively), and the staging accuracy is variable with a sensitivity (specificity) 
of 80%, 63% and 38% respectively (53%, 94% and 100%, respectively). For image 
quantifications, the inter-observer agreement is good (ICC=0.56-0.98) and the 
measured parameters show significant correlations to established staging criteria. 
Tumor apparent diffusion coefficient (ADC) value on diffusion-weighted imaging 
(DWI) is significantly lower in tumors with deep myometrial invasion (ADC = 0.75 × 
10-3mm /s) compared with tumors with superficial or no myometrial invasion (ADC = 
0.85 × 10-3mm /s; p < 0.001), and the ADC value is negatively correlated to tumor 
size (p=0.007). Large tumor size measured on preoperative MRI is associated with 
reduced progression/recurrence free survival (p ≤ 0.005 for all size parameters), and 
2
2
CC diameter has an independent impact on survival (adjusted hazards ratio, 1.04; p = 
0.009). FDG-PET/CT is excellent in ruling out lymph node metastases (NPV=97%) 
and SUVmax, SUVmean, MTV and TLG are significantly related to deep myometrial 
invasion, presence of lymph node metastases and high histological grade (p<0.015 for 
all). Calculated optimal cut-off values for MTV in predicting deep myometrial 
invasion (20 ml) and presence of lymph node metastases (30 ml), yield ORs of 7.8 
(p<0.001) and 16.5 (p=0.001), respectively, outperforming the current pre-operative 
ground for decision-making based on pathology findings in endometrial biopsies. 
 
Conclusion: Functional and structural imaging biomarkers from MRI and FDG-
PET/CT are promising for preoperative identification of high-risk patients in 
endometrial carcinoma.  
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Cancer of the endometrium (the inner lining of the uterus) is the most common pelvic 
gynecologic malignancy in industrialized countries and the seventh most common 
malignancy amongst women worldwide (1, 2). The incidence differs between 
continents, and is presently ten times higher in Europe and North-America, than in less 
developed regions of the world. Increasing incidence is registered, supporting the 
notion that environmental factors like obesity and physical inactivity contribute to the 
development of the disease, in addition to increased life-expectancy. In developing 
countries, endometrial cancer is the second most common gynecologic malignancy 
(cervical cancer being by far the most common), but the specific mortality rate is 
higher (1) .  According to the Cancer Registry of Norway, 656 new patients were 
diagnosed with uterine cancers in Norway in 2012, and 92 women died from the 
disease in 2011. The life-time risk of developing the disease is 2.0% (3), with 
comparable figures for the rest of the Western world (1, 2). The five-year survival rate 
is high, reaching 84.3% in the latest figures from the Cancer Registry of Norway (3). 
In international studies, the 5-year survival for all stages taken together, is reportedly 
around 80% (1). 
 In Europe around 9000 women are estimated to die from endometrial cancer 
every year, and no considerable decrease in this number can be expected within the 
nearest future, as neither early detection nor different treatment approaches have 
significantly influenced mortality (1). On a worldwide basis, the annual figures for 
disease-specific deaths are 42,000. 
 The median age at diagnosis in Norway is 66 years, and the highest incidence is 
found in the group aged between 70-74 years. Endometrial cancer is relatively rare 
among premenopausal women, and is rarely diagnosed in patients below the age of 35 
years; still the need for fertility-preserving therapy is relevant for women in 
childbearing age. At the time of diagnosis, 74.4% of patients have tumors confined to 
the uterus (NORDCAN 2007-11).     
 
2.2 ETIOLOGY, PATHOGENESIS AND RISK FACTORS 
80-90% of endometrial cancers are adenocarcinomas arising from endometrial cells, of 
which the endometrioid carcinoma is the most common subtype (1). Endometrioid 
tumors typically present at an early stage with abnormal uterine bleeding, and tend to 
have a favorable prognosis (2). Non-endometrioid subtypes (e.g. serous, clear cell, 
undifferentiated, carcinosarcoma) are classified as high-risk, and associated with 
considerably poorer prognosis (1). Overall, up to 20% of endometrial carcinomas 
follow an aggressive course (2).  
The most prevalent and considered main risk factor for developing endometrial 
carcinoma is excess endogenous or exogenous estrogen stimulation, not 
counterbalanced by progesterone. This factor is linked to endometrioid endometrial 
carcinoma in particular, also classified as type 1 tumors (except for grade 3 
endometrioid endometrial carcinoma, which is classified as type 2) (1). Excess 
estrogen relative to progesterone stimulates endometrial cell proliferation, inhibits 
apoptosis and promotes angiogenesis, all processes favoring carcinogenesis. Other risk 
factors for type 1 tumors include obesity, null parity, diabetes mellitus and 
hypertension. Reported relative risk of endometrial cancer related to presence of 
different risk factors are given in Table 1. 
The main source of exogenous estrogen stimulation is postmenopausal estrogen 
therapy without opposing progesterone, resulting in a markedly increased risk of 
endometrial hyperplasia and carcinoma, with reported relative risk ranging from 1.1 to 
15 (4-6).   Also, Tamoxifen treatment is reported to increase risk in postmenopausal 
women whereas no increased risk in premenopausal women has been established (7).  
Common causes of endogenous estrogen stimulation are excessive conversion 
of adrenal precursors to estrogen and estradiol by adipose cells in obese women (8) 
and chronic anovulation where sex steroid hormones, including estrogen unopposed by 
adequate progesterone production, are produced continuously and induce 
uninterrupted proliferation of the endometrium (9). For the most common disease 
associated with anovulation, polycystic ovary syndrome (PCOS), a recent study 
indicates that the increased risk of endometrial cancer may be overestimated (10). In a 
meta-analysis of 19 prospective studies including over three million women, an 
increase in body mass index (BMI) of 5 kg/m2 incurred a significantly increased risk 
of developing endometrial carcinoma with reported relative risk (RR) of 1.59 
(confidence interval (CI) of 1.50-1.68) (11). 
Early menarche and late menopause are reported risk factors in some studies 
(12), but not  in all studies (13). The tentative explanation for increased risk under 
these circumstances is prolonged estrogen stimulation during a life span. 
Lynch syndrome (hereditary nonpolyposis colorectal cancer) leads to a life time 
risk of endometrial carcinoma of 40-60% and accounts for 2-5% of all endometrial 
carcinomas. Women with Lynch syndrome tend to develop endometrial carcinoma at 
an earlier age (46-54 years), but the disease usually presents at an early stage and has a 
course similar to sporadic endometrial carcinomas (14).  
Having a first degree relative with endometrial carcinoma has been suggested as 
a risk factor, and a meta-analysis of 16 comparative studies concluded on a RR of 1.82 
(95% CI 1.65-1.98); however, only three of these studies excluded patients with Lynch 
syndrome (15). The cumulative risk of endometrial cancer up to 70 years in women 
with a first-degree relative with endometrial cancer was estimated to be 3.1% 
compared with <2.0% in the general population. 
 Non-endometrioid tumors are not clearly associated with estrogen stimulation. 
They account for 10-20% of endometrial carcinomas, are classified as high-grade and 
have a poor prognosis. Unlike endometrioid tumors, non-endometrioid tumors are 
commonly associated with p53 mutations, aneuploid karyotype and human epidermal 
growth factor receptor 2 (HER-2)/neu overexpression (1).  Serous carcinoma is 
believed to develop by transformation of the endometrial surface epithelium in an 
atrophic endometrial environment (16). In this group, 70% of the patients present with 
advanced stage (stage 3 or 4) with tumor extension beyond the uterus. The 
corresponding number for clear cell carcinomas is 50% (17, 18). No clear 
epidemiologic risk factors have been identified for non-endometrioid tumors, but one 
study of more than one million Norwegian women followed for an average of 25 years, 
found that obesity was associated with increased risk also in the non-endometrioid 
subtype, although less pronounced than for the endometrioid subtype (19). 
 








Tamoxifen therapy 2 
Late menopause (after age 
55) 
2 
Null parity 2 
Polycystic ovary syndrome 3 
Obesity 2-4 








13-19% lifetime risk 
*other statistics are noted when used 
Adapted from data in Smith RA, von Eschenbach AC, 
Wender R, et al. American Cancer Society Guidelines 





Endometrial cancers are often classified as type I or type II endometrial tumors, type I 
being the low-grade endometrioid cancers, including cases with squamous cell 
differentiation, and type II comprising high-grade endometrioid tumors and non-
endometrioid tumors as serous, clear-cell, mucinous and mixed carcinoma, and the 
more rare subtypes squamous-cell, transitional-cell, small-cell and undifferentiated 
carcinoma and currently also carcinosarcomas (1). 
The endometrioid subtype is commonly well-differentiated adenocarcinomas 
with a gland-forming growth pattern, easily recognizable in the microscope (1).  
Histologic grading is decided by assessing gland formation and nuclear atypia. 
 Serous and clear cell carcinomas are more invasive and aggressive. Serous 
carcinomas have a complex papillary architecture, resembling the serous carcinoma of 
the ovary. The papillae are often covered with highly pleiomorphic tumor cells with 
frequent mitosis and necrosis (1).  Nearly all serous carcinomas are characterized by 
distinct p53 antigen-staining on immunohistochemistry. Clear cell carcinomas are 
characterized by tubulocystic, papillary and solid patterns. These lesions often involve 
the surface of a benign, endometrial polyp, the cytoplasm is clear and cell walls are 
distinct (1). Gene expression profile shows a specific pattern in clear cell carcinomas, 
but in contrast to serous carcinomas, they are negative to p53 mutations. The 
cytoplasm of the tumor cells contains glycogen, thus the clear appearance.  
In cases where endometrioid carcinomas are difficult to distinguish from the 
serous/mixed type, genetic profiling can aid by showing microsatellite instability 
(MSI) and specific mutations (PTEN, K-ras, beta-catenin) in the endometrioid 
subtype, contrasting the p53 mutations that characterize the non-endometrioid subtype.   
Some rare histologic subtypes classified as non-endometrioid endometrial 
carcinomas are squamous cell (an invasive tumor forming well differentiated 
squamous pearls), transitional cell (a neoplasm forming papillae lined by low grade 
stratified transitional type epithelium), mucinous (with tumor cells often containing 
voluminous intracytoplasmic mucin), and small cell (tumor composed of small cells 
with high nuclear to cytoplasmic ratio), constituting <2% of all endometrial 
carcinomas (20). 
                                                                                                                                                       
2.4 CLINICAL FEATURES 
2.4.1 Biopsy, cytology and curettage 
Abnormal uterine bleeding is the most typical early symptom in endometrial cancer, 
most commonly found among postmenopausal women and with increasing age in 
premenopausal women.  Suspicion of endometrial neoplasia (hyperplasia or 
carcinoma) will depend on the severity of symptoms, age and the presence of risk-
factors.  Abnormal bleeding pattern is found in 75-90% of women with endometrial 
cancer (21-23), whereas a small percentage of patients present with no abnormal 
uterine bleeding, but with atypical findings on cervix cytology. 
 The first step in the initial work-up of patients suspected of having endometrial 
neoplasia is endometrial sampling, usually performed by curettage producing an 
endometrial biopsy. If the material is sparse or unfitted for histopathological 
evaluation, a dilatation and curettage (fractionated curettage) is performed, collecting 
specimens from the endometrial lining and the cervix separately. Cancers can be 
distinguished from benign samples by endometrial cytology only, but supplementary 
samples of the endometrial mucosa are needed for preoperative histologic subtyping 
and grading. The histopathological diagnosis lays the basis for the planning of all 
further treatment.  Patients are categorized into low- and high risk disease based on 
subtyping and grading. Non-endometrioid subtypes and high-grade endometrioid 
subtypes are regarded as high risk phenotypes, more likely to represent aggressive 
disease with increased risk of extra-uterine spread and poor prognosis (24, 25).  
 
2.4.2 Sonography 
Transvaginal ultrasonography (TVUS) is routinely used by gynecologists as a 
diagnostic tool in the evaluation of postmenopausal bleeding. It has the benefit of low 
cost and immediate availability in every gynecologist’s practice.  The method is well 
suited to depict the thin endometrial lining in postmenopausal women and the reported 
sensitivity and specificity for detection of endometrial carcinoma is 96% and 61%, 
respectively, when applying a threshold of 5mm for normal endometrial thickness 
(26).  The evaluation of premenopausal women is more challenging due to the cyclical 
changes in thickness of the endometrium. 
 A recent meta-analysis reported a sensitivity of 68-100% and a specificity of 
71-90% for the subjective assessment of deep myometrial invasion by TVUS, while 
the reported sensitivity and specificity for assessment of cervical stromal invasion are 
ranging from 19-100% and 82-99%, respectively (27). 
 There are insufficient data on the performance of TVUS in the detection of 
lymph node metastases (28), but the limited field of view is a challenge and will also 
rule out the possibility of finding lymph node metastases outside the pelvis.   
 
2.4.3 Radiological diagnostics 
Computed tomography (CT) of the thorax, abdomen and pelvis is widely applied 
preoperatively for the detection of lymph node metastases and distant spread.  For 
local status in the pelvic area, magnetic resonance imaging (MRI) is considered 
superior (29-31), and serves as part of the standard preoperative work-up for 
endometrial carcinoma patients at many centers. Neither CT nor MRI, however, is 
considered sufficiently accurate for the prediction of lymph node metastases or deep 
myometrial invasion (1, 29, 31). 18F-fluorodeoxyglucose Positron Emission 
Tomography/Computed Tomography (18F-FDG-PET/CT) is costly, and although it is 
considered promising, especially for detection of metastases, its role in the 
preoperative staging of endometrial cancer is not yet established (1, 32-35). 
 
2.4.4 Serological analyses and tumor biomarkers 
No serological analyses are routinely applied for diagnostics of endometrial 
carcinoma. Several studies support CA-125 in the preoperative work-up (36-39), and a 
future role of CA-125 in a preoperative risk assessment algorithm and as a marker of 
disease progression seems likely (40-42). Also serum calprotectin and growth 
differentiation factor (GDF) 15 have been linked to aggressive phenotype in clinical 
studies (2). 
 Several molecular biomarkers of the primary tumors have also been identified 
in endometrial carcinomas. Presence of estrogen and progesterone receptors, 
transcription factor GATA3, Stathmin overexpression, DNA ploidy and p53/p16 
staining are linked to prognosis in retrospective and prospective studies (43-45), but 
for implementation in risk stratification models, further studies are needed (2). Drugs 
targeting the PI3/PTEN/AKT/mTOR pathway and FGFR2 have been identified and 
seem promising in molecular studies (46); ongoing phase 1 and 2 trials will further 
evaluate the benefit of this therapeutic approach.  
 
2.5 IMAGING CHARACTERISTICS 
2.5.1 Sonography 
TVUS is often the first-line imaging method applied to evaluate possible etiologies of 
abnormal vaginal bleeding. In postmenopausal women without risk factors, an 
endometrial thickness of 4-5 mm assessed by TVUS is associated with low cancer 
risk (47-49). When the endometrium reaches a thickness of 20 mm, cancer becomes 
more frequent relative to benign disease (48). TVUS may also be useful to identify 
non-malignant structural lesions of the uterus (e.g. polyps, myomas) as possible 
differential diagnosis for abnormal bleeding episodes.  In premenopausal women, the 
use of TVUS to exclude endometrial disease is not established (50, 51), as there is no 
defined threshold for endometrial thickness to validly differentiate between benign and 
malignant endometrial thickening in this younger patient group.  
 
2.5.2 Magnetic resonance imaging 
For preoperative evaluation of endometrial carcinoma patients, conventional MRI 
including two T2-weighted sequences in sagittal, axial oblique or coronal oblique 
orientation (short and long axis of the uterus) and contract-enhanced, T1-weighted 
sequences including post-contrast images acquired 2 min ± 30 s after contrast medium 
injection is recommended in recent guidelines (52), in addition to a section orientated 
perpendicular on the axis of the endocervical channel, to evaluate cervical invasion. 
On T2-weighted images, the majority of endometrial carcinomas have a 
heterogeneous and mainly hyperintense appearance compared to the normal 
myometrium (28, 53) (Fig 1 A, B) but some tumors may be iso- or hypointense (Fig 2 
A,B). Endometrial irregularities, lobulation or local thickening  may also point towards 
the diagnosis (53). 
   
 
Unenhanced T1-weighted images depict endometrial carcinomas isointense to 
the adjacent myometrium (53), while contrast-enhanced T1-series typically exhibit 
endometrial carcinomas as less enhancing than the highly vascularized myometrium 
(30, 54-56) (Fig 1 C and 2 C). 
The preoperative evaluation of pelvic MRI in endometrial carcinoma patients 
aims to assess the depth of myometrial tumor invasion (≥/< 50%), and identify 
presence of cervical stromal invasion and lymphatic spread.  The diagnostic 
performance of contrast-enhanced MRI is well documented for myometrial and 
cervical tumor invasion, and considered superior to that of ultrasonography, CT and 
unenhanced MRI (28, 31, 53). For lymphatic spread, the performance is however 
rather low, with reported sensitivities of 17-80%  in recent literature(56). A recent 
meta-analysis including 52 studies examining MRI in the assessment of high-risk 
features of endometrial carcinoma found pooled sensitivity (specificity) of 80.7% 
(88.5%) for ≥50% myometrial invasion, 57% (94.8%) for cervical stromal invasion 
and 43.5% (95.9%) for lymph node spread, respectively (57). Given the rather low 
results on sensitivity, the authors conclude that patients with negative findings on MRI 
should not forgo surgical staging. 
Nevertheless, MRI has long been the preferred imaging tool in the preoperative 
staging for treatment planning in endometrial carcinoma patients, and in particular in 
the evaluation of disease spread within the pelvic region (1, 31, 58). The considerable 
variation in reported accuracy of MRI in the detection of important staging parameters 
(56, 59-61) may be due to different MRI protocols applied, as well as interobserver 
variability in the interpretation of the images. When introducing MRI as a diagnostic 
tool in preoperative staging, the validity and reproducibility of the method must be 






Diffusion-weighted imaging (DWI) is a functional imaging technique routinely 
in use at many centers as an adjunct to conventional MRI for preoperative staging of 
endometrial carcinomas (56, 62, 63), and it may aid in the differentiation between 
benign and malignant lesions (56). Endometrial carcinomas typically exhibit restricted 
diffusion with decreased apparent diffusion coefficient (ADC) values compared to the 
surrounding normal myometrial tissue (56), appearing as brightly hyperintense on the 
DWI series (Figs. 1D, 2D) and hypointense on the corresponding ADC map (Figs. 1E,  
2E). Reported mean ADC values range from 0.84-0.98x 10-3 mm2/s in endometrial 
carcinomas, 1.21-1.76x10-3 mm2/s in benign lesions, 1.45-1.71x10-3 mm2/s in normal 
endometrium, and 1.53-1.65x10-3 mm2/s in normal myometrium (63-67). 
 Other novel MRI methods like MR perfusion, spectroscopy, and BOLD-MRI 
may represent additional MR tools for preoperative staging and tumor characterization 
in endometrial carcinomas  in the future, but these techniques are not yet fully 
explored for endometrial cancer (56).  
 
2.5.3 18-Fluoro-Deoxy-Glucose (FDG)-Positron Emission Tomography (PET) / 
computed tomography (CT) 
This non-invasive, functional diagnostic imaging method uses a radio-labelled glucose 
analogue (2-deoxy-2-(18F) fluoro-D-glucose) as tracer, and takes advantage of the 
increased glucose metabolism in malignant cells to identify cancer in human tissue. 
CT images for attenuation correction and anatomic correlation are acquired 
successively in the same gantry system, allowing co-registration, reconstruction and 
combination into a single, superposed imaging series.      
FDG-PET/CT is currently not routinely in use for the preoperative evaluation of 
endometrial cancer in most centers. It is, however, the preferred imaging method for 
staging of many cancer types (68), and the diagnostic value  in endometrial  
carcinomas  is currently the subject of recent and ongoing research (32-35, 69-74).  
The primary endometrial tumor is normally highly FDG-avid (Figs 1F and 2F) 
if the size of the tumor is >5 mm with reported mean preoperative maximum 
standardized uptake value (SUVmax) of 14.3 (range 3.9-33.8) in a recent study of 101 
patients (75), and 11.2 (SD of 5.9) in a review from 2010 (76). When FDG-uptake is 
seen also in the cervix, this may suggest cervical stromal invasion. Down to the size of 
5 mm, lymph node metastases are usually detectable by increased FDG-uptake, and for 
endometrial carcinoma patients, the whole-body scanning is advantageous for 
detecting para aortic lymph node metastases that may be present in addition to, or in 
the absence of pelvic lymph node metastases. The sensitivity, specificity and accuracy 
of PET/CT in detecting  lymph node metastases are reportedly 53-86%, 92-99% and 
91-98%, respectively (33, 77). Antonsen et al. (33) reported sensitivity, specificity and 
accuracy also for deep (≥50%) myometrial invasion and cervical invasion to be 88.9%, 
43.5%, 63.9% and 38.5%, 92.8%, 81.3%, respectively.  
Additionally, recent literature reports that preoperative SUVmax of endometrial 
tumors is an independent prognostic marker of recurrence and death (70), and an 
important indicator of tumor aggressiveness and high-risk disease (34, 69, 75). Other 
FDG-PET-specific quantitative measurements like SUVmean, metabolic tumor 
volume (MTV) and total lesion glycolysis (TLG) have also recently been explored as 
prognostic markers. MTV and TLG have appeared as significant predictors of several 
clinical pathological characteristics and these parameters are superior to SUVmax in 
differentiating high-risk from low-risk patients in a recent study of 56 endometrial 
carcinoma patients (69). In addition, MTV is suggested in the literature as a promising 
marker for lymph node metastases and poor outcome (71, 78). SUVmean has been less 
studied, but similar to SUVmax, it has been associated with International Federation of 
Gynecology and Obstetrics (FIGO) stage, histologic grade and maximum tumor size in 
endometrial cancer (72). 
 
2.6 STAGING 
Endometrial carcinoma is surgically staged according to the 2009 FIGO classification 
system (79) (Table 2). In the prior surgical staging system (FIGO 1988 staging 
system), stage I had three substages, but stage IC had a poorer survival than stage IIA, 
and stage IIIC did not differentiate between  patients with pelvic and para aortic lymph 
nodes, although the prognosis between these groups is significantly different. The 
current system better reflects treatment relevant prognostic groups after eliminating 
these contradictions by merging former stage IA and IB (currently IA), eliminating the 
former stage IIA, and stratifying stage IIIC into IIIC1 (pelvic lymph node metastases) 
and IIIC2 (para aortic lymph node metastases) (80).  
For the complete surgical staging procedure, a total hysterectomy with bilateral 
salpingo-oophorectomy with pelvic and para aortic lymph node dissection is 
recommended. Pelvic and para aortic lymph node sampling or removals are performed 
selectively, but as a minimum, these nodes are palpated during surgery and suspicious 
or enlarged lymph nodes are removed if possible. The extent of uterine disease is 
evaluated during surgery by gross examination of the surgical specimen, and provides 
some guidance to the extent of staging needed for each individual (for instance if 
lymphadenectomy is required). Surgical treatment is also guided by the assessment of 
tumor subtype and grade provided by the pathologists from the preoperative 
endometrial biopsies and preoperative imaging findings. 
Results from the surgical staging procedure further guide the clinician in 
deciding which patients should be recommended adjuvant treatment. This decision is 
also based on the histopathologic subtype detected in the initial and final 






















IA Tumour confined to the uterus, < 50% myometrial invasion 
IB Tumour confined to the uterus, ≥ 50% myometrial invasion 
II Cervical stromal invasion, but not beyond uterus  
IIIA Tumour invades serosa or adnexa 
IIIB Vaginal and/or parametrial involvement 
IIIC1 Pelvic node involvement 
IIIC2 Para-aortic involvement 
IVA Tumour invasion bladder and/or bowel mucosa 
IVB Distant metastases including abdominal metastases and/or 
inguinal lymph nodes 
2.7 TREATMENT 
2.7.1 Surgery including lymphadenectomy 
Surgery is the cornerstone in primary endometrial cancer treatment, and usually 
curative for women with low-risk disease confined to uterus (1). The standard 
procedure comprises total hysterectomy with bilateral salpingo-oophorectomy. If the 
tumor invades the cervix (stage II), an extended, radical hysterectomy procedure is 
recommended, including excision of paracervical and parametrial structures. Most 
surgeons also perform peritoneal washing for cytological diagnostics, but results will 
not guide further treatment as an integrated part of the FIGO staging after the revision 
in 2009. In case of evident intraperitoneal metastases, debulking is recommended, in 
line with the experience from debulking surgery in ovarian cancer surgical treatment, 
although the survival benefit is uncertain (81).  If histology has confirmed clear cell or 
serous carcinoma, omentectomy is frequently performed as these subgroups have a 
high frequency of intra-abdominal spread and may clinically often resemble ovarian 
carcinomas (82). 
 Lymphadenectomy is recommended as part of a complete surgical staging 
procedure according to the FIGO (79, 83). A total staging lymphadenectomy normally 
includes the left and right common, external and internal iliac and obturator chains, in 
addition to left and right para aortic nodes. Tumor infiltration of more than 50% of the 
myometrial wall is an established marker for significantly increased risk of lymph 
node metastases (1, 83), and represents one of the main factors in the preoperative 
decision-making regarding the extent of lymphadenectomy performed during primary 
surgery (84, 85). The approach to lymph node assessment is, however, controversial, 
particularly in women preoperatively classified as low-risk patients (86). The extent to 
which lymphadenectomy is actually performed varies considerably between centers. A 
survey among tertiary cancer centers in USA reported that 45% routinely performed 
the procedure (87), while 24% of European centers reported lymphadenectomy as 
routine procedure in endometrial cancer surgery (88).  
 The Norwegian guidelines (Salvesen et al. Endometriecancer, Kvalitetsutvalget 
Norsk Gynekologisk Forening, 2009) were revised in 2009 to recommend 
considering pelvic lymph node sampling for medium-risk patients and pelvic and para 
aortic lymphadenectomy for high-risk patients, according to risk stratification based on 
preoperative assessment of subtype and grade and the extent of myometrial invasion.  
 Although it is established that the presence of metastatic lymph nodes is a 
strong predictor of poor prognosis, with a 5-year survival of 57% compared to 74-91% 
for stages with no lymph node spread, the survival benefit from lymph node sampling  
is not well documented, and no survival benefit has been found in randomized trials, 
and for low-risk groups in particular (89). Also, the risk of complications (lymph 
edema, lymph cyst formation and surgically related systemic complications) in lymph 
node sampled patients is significantly increased (86), and the subject remains an issue 
of controversy. 
 Surgery is performed by open laparotomy, laparoscopy or robot-assisted 
laparoscopy. In selected cases with medical comorbidities or severe obesity vaginal 
hysterectomy may be performed, but is generally not recommended (90, 91) .  
 
2.7.2 Adjuvant therapy 
Radio- and chemotherapy 
Radiotherapy can be offered vaginally as brachytherapy (VB), as external radiation to 
the pelvis (EBRT) or to an extended region comprising the para aortic area or the 
whole abdomen. Radiotherapy is widely used and reduces pelvic relapse from about 
20% to 5%, but the effect on survival for patients with stage I tumors have not been 
documented (92) and radiation is no longer recommended routinely in low-risk 
patients with FIGO stage I endometrioid grade 1 or 2 disease with <50% invasion of 
the myometrium (93). Brachytherapy is locally effective and associated with a 
significant reduction in long-term side effects (the most common being bowel 
obstruction and chronic diarrhea) (92), but for high-risk cases (including higher tumor 
stages and tumors with non-endometrioid histology), external radiation therapy is still 
the treatment of choice (94), also reflected in the revised Norwegian National 
guidelines (95).  
 Chemotherapy is increasingly recommended for patients with high-risk 
endometrial carcinomas, although the optimal regimen is yet to be better defined. It 
can be administrated as a single-agent therapy or in combinations; the most commonly 
used drug combination in Norway is currently carboplatin and paclitaxel, although 
other combination therapies including cisplatin, paclitaxel, ifosfamide or doxorubicin 
are options, all producing response rates of 20-37% (96). Undesired side effects of 
combination therapies tend to exceed those of single-agent therapy, and include 
leukopenia and cardiotoxicity. From 1996 to 2001, the reported portion of patients 
with endometrial carcinoma receiving adjuvant chemotherapy has increased, in line 
with current recommendations (83). 
 
Anti-hormonal therapy 
Endometrial cancer patients are no longer subjected to anti-hormonal therapy as 
adjuvant treatment due to lack of support for efficacy. A large Cochrane review of six 
randomized controlled trials with both adjuvant and recurrent settings could not find 
sufficient evidence for any survival benefit of anti-hormonal treatment (97). Not all 
included trials had, however, incorporated the tumor hormone-receptor status. It may 
thus be argued that trials including hormonal status in order to stratify patients for anti-
hormonal treatment are needed to evaluate the true potential of anti-hormonal therapy 
in selected patient groups, also in line with current practice for breast cancer therapy 
(98).  
 
2.8 PROGNOSTIC FACTORS AND OUTCOME 
For the majority of endometrial carcinoma patients the prognosis is excellent (80-90% 
5-year survival), due to early detection of uterine confined disease of most commonly 
the endometrioid subtype. The strongest prognostic factor in endometrial carcinoma 
patients is FIGO stage (Table 2), where survival is significantly lower in the higher 
stages. The reported 5-year survival is 90% for stage IA, 78% for IB, 74% for stage II, 
36-57% for stage III depending on the site of extra-uterine tumor manifestation and 
21/22% for stage IVA /IVB, respectively (80). Moreover, a study of 27 000 
endometrial carcinoma patients identified myometrial invasion of >50% as an 
independent risk factor for advanced, high-stage disease with metastatic spread and 
poor survival (99). The same study, a large trial from the American Surveillance, 
Epidemiology, and End Results Program (SEER) registry, also found that the presence 
of pelvic or para aortic lymph node metastases was associated with significantly lower 
survival even when adjusted for uterine risk factors such as cervical stromal invasion, 
deep myometrial invasion and high histological grade, and thus represents an 
independent prognostic marker for poor outcome (99).  
 Other strong predictors of outcome are histological subtype and grade. The non-
endometrioid subtypes have significantly worse outcome than tumors with 
endometrioid histology; the reported 5-year survival for non-endometrioid tumors 
within stage I is 78-85%, contrasting 90-93% for patients with endometrioid histology,  
and undifferentiated high-graded tumors, also within the endometrioid group, have 
significantly lower survival than the well differentiated low-grade tumors (83).  
Lymphovascular space invasion is a histological tumor feature often linked to 
poor outcome (100), and the importance of the pathologists reporting this information 





3. Specific background and aims of the study                               
Specific background  
Endometrial carcinoma is the most common gynecological malignancy in 
industrialized countries, and the incidence is increasing attributed to epidemic obesity 
(1). Treatment and prognosis is influenced by surgical International Federation of 
Gynecology and Obstetrics (FIGO) stage i.e. depth of myometrial invasion, cervical 
extension, and lymph node, pelvic or distant metastases (1, 2). Also, histologic subtype 
and tumor grade have prognostic impact (1). Depending on tumor stage, the 5-year 
survival for endometrial carcinoma patients range from 20% to 91%, with generally an 
80% survival rate reflecting that 75% of cases are diagnosed at early stage (83). There 
are few treatment options for women with recurrent, metastatic or inoperable disease. 
Response rates to hormones are modest in the range of 9-25% and prognosis is poor. 
The most active chemotherapy regimen has a response rate of up to 60%; however, 
overall survival is short and is associated with significant toxicity in a largely elderly 
population. Knowledge of tumor dissemination prior to surgery is critical in 
determining the treatment strategy for each individual patient. The prognostic 
unfavorable impact of deep myometrial invasion is well established (101), and 
accurate preoperative identification of deep myometrial infiltration and cervical 
stromal involvement is important to tailor surgical treatment to also include 
lymphadenectomy and radical hysterectomy, respectively (2). It is established that 
low-risk patients do not necessarily benefit from lymphadenectomy as this procedure 
is associated with more complications (86). 
 The present project focuses on preoperative characterization of endometrial 
carcinomas by structural and functional MRI and FDG- PET/CT in combination with 
histological and molecular classification of endometrial biopsies. The overall aim of 
the project is to promote individualized treatment, reduce morbidity, and facilitate 
implementation of targeted therapy amongst these patients. Non-invasive imaging 
methods may potentially aid the preoperative identification of high-risk patients before 
primary surgery. This can provide a better basis for individualized treatment, planning 
of the surgical procedure, and referral to specialized units. Furthermore, it may 
potentially reduce the morbidity from extensive lymphadenectomy in the low-risk 
groups. 
 
Aims of the study 
1. To evaluate the diagnostic performance of pelvic MRI as well as interobserver 
agreement for the detection of deep myometrial invasion, cervical stroma 
invasion and lymph node metastases in endometrial carcinoma patients in 
relation to surgical staging (Paper I).  
 
2. To explore the utility of ADC value measurement on DWI in the preoperative 
evaluation of endometrial carcinomas and to investigate the potential of tumor 
ADC value as a biomarker reflecting clinical and histological tumor 
characteristics. A further aim was to assess the interobserver agreement for 
measurement of ADC values and for preoperative evaluation of staging 
parameters based on standard pelvic MRI including DWI (Paper II). 
 
3. To explore the relationship between different preoperative tumor size 
measurements using MRI and the surgical pathological staging parameters deep 
myometrial invasion, cervical stromal invasion and metastatic lymph nodes. 
Secondarily to assess the interobserver variability for the different tumor 
measurements and to explore the value of these preoperative tumor size 
measurements to identify patients with poor outcome (Paper III). 
 
4. To prospectively explore the diagnostic value of preoperative FDG-PET/CT for 
staging purposes in endometrial carcinomas, and to investigate to what extent 
FDG-PET-specific quantitative tumor parameters reflect clinical and 
histological tumor characteristics. To further explore clinical applicability we 
also aimed to assess interobserver agreements for FDG-PET/CT staging- and 
quantitative tumor parameters and to review the prevalence and significance of 
incidental findings in the context of prospective and consecutive FDG-PET/CT 
investigations of a population based endometrial carcinoma cohort (Paper IV).  
4. Materials and methods 
4.1 PATIENTS AND DATA COLLECTION 
Since April 2009, all patients with histologically confirmed endometrial carcinoma at 
Haukeland University Hospital have been consecutively referred to preoperative pelvic 
1.5-T MRI in a prospective setting. The diagnosis is verified in hysterectomy 
specimens and final stage is established based on surgical staging. From October 2010, 
the same patient group was also prospectively included in a study of preoperative 
FDG-PET/CT, to further evaluate the usefulness of advanced imaging methods for 
staging and assessment of potential imaging biomarkers for aggressive disease and 
poor outcome. The patients signed informed consent for collection of data and 
specimens for biomarker studies under institutional review board-approved protocols. 
All participants were diagnosed and treated at Haukeland University Hospital; a 
European Society for Gynecologic Oncology (ESGO) accredited training center for 
gynecologic oncology, serving a population of ~1 million inhabitants.  
 Paper I included 67 patients with suspected endometrial carcinoma 
prospectively referred to preoperative MRI. Ten of the patients were excluded, due to 
change in the final diagnosis (endometrial hyperplasia in six patients, an endometrial 
polyp in one patient and one patient was diagnosed with cervical cancer), lack of 
surgery/histologic diagnosis (n=1) or incomplete MRI (n=1), leaving 57 patients with 
confirmed endometrial carcinoma eligible for further analyses. 
 Paper II included 105 consecutive patients referred to preoperative MRI up to 
December 2011, partially overlapping the cohort of Paper I. Also in Paper III the 
cohort is partially overlapping the preceding, but it includes patients consecutively 
referred up to December 2013, yielding a patient sample of 212. 
 In the FDG-PET/CT based study (Paper IV), 129 consecutive patients were 
included, inclusion ending in September 2013. The images were acquired 
prospectively and the results reported to the responsible clinician together with all 
relevant preoperative imaging performed. In this cohort, the medical records for all 
patients with significant incidental findings (defined as imaging findings without link 
to endometrial cancer, but with a possible therapeutic consequence) were examined 
retrospectively  ~ one year after the PET/CT scan to register how the clinical team had 
dealt with the follow-up of the incidental findings. 
 Image reading for staging parameters, reproducibility assessments and 
quantifications were all conducted retrospectively. The follow-up data regarding 
recurrence, progression and survival, have been collected from patient records and 
from correspondence with the responsible primary physicians or gynecologists. The 
FIGO 2009 criteria (79, 80) were used for staging of all patients, and this was used as 
the reference standard throughout the studies. Surgical specimens were sectioned 
along the longitudinal plane of the uterus, and depth of myometrial invasion and 
presence of cervical stromal invasion were estimated macroscopically and confirmed 
microscopically according to standard procedures (102). Routine histopathology 
reports were generated in a tumor board setting and the reporting pathologists were 
blinded to the result of preoperative imaging. The responsible surgeon decided the 
extent of lymph node sampling based on knowledge of histologic risk profile in the 
endometrial biopsy, results of preoperative imaging and the patient’s general health 
condition. The operating gynecologist then labelled all lymph nodes according to 
anatomical localization (common, internal and external iliac, internal obturator and 
lumboaortic node groups) and the pathologists documented number and size of the 
metastatic lymph nodes. 
 
4.2 IMAGE READING 
4.2.1 MRI reading 
All images were deidentified and read independently by four (Paper I) or three 
(Paper II and III) observers blinded for clinical data, tumor stage, histological 
diagnosis and patient outcome. The observers’ experience in pelvic imaging ranged 
from 2 to >10 years, and the pool included both residents and consultants. All 
observers reported the imaging findings in a standardized form (appendix).   
For Paper I they recorded primary location, number, size (AP, width and 
height), minimum distance from tumor to serosa, maximum depth of myometrial 
invasion and margins (sharp, moderately sharp or diffuse) of the endometrial tumors. 
Contrast-enhanced (CE) T1-weighted images were used to measure tumor size (except 
sagittal diameter as sagittal CE T1-weighted images were not acquired), distance from 
tumor to serosa and depth of myometrial invasion (assessed at the deepest point in 
which the tumor extends into the myometrium). Tumor signal intensity relative to 
normal myometrium (lower, similar or higher) was recorded on T1-weighted and T2-
weighted unenhanced series and CE T1-weighted series. Cervical stromal invasion 
(defined as disruption of the low-signal intensity cervical stroma on T2-weighted 
images), tumor growth in serosa, adenexa, vagina, bladder or rectum, intraperitoneal 
fluid, enlarged para aortic or para iliac lymph nodes (largest short-axis diameter > 
10mm), distant metastases and concomitant findings such as uterine adenomyosis and 
myomas were recorded. Before analysis, the recorded presence (yes / no) of the three 
following findings was noted: 
1. Deep myometrial invasion (tumor invading ≥50% of the myometrium) 
2. Cervical stromal invasion 
3. Enlarged pelvic or para aortic lymph nodes 
 
For Paper II, the staging parameters and the measurements of tumor diameters 
were assessed on T2-weighted and CE T1-weighted images, using DWI only as a 
supplementary sequence guiding the measurements performed on the conventional 
series.  The overall quality of the DWI was considered, and images with major 
artefacts (e.g. due to hip implants blurring the anatomy) were excluded from the DWI 
analyses (five of 105 cases). A region of interest (ROI) was manually drawn in the 
ADC map depicting the largest part of the tumor in each patient. The ROI aimed to 
comprise a representative part of the tumor tissue in closest proximity to normal 
myometrial tissue (in order not to falsely include normal tissue), and also leaving out 
necrotic or hemorrhagic areas if present (Fig. 3). Median volume of the drawn ROIs in 
tumor tissue was 0.88 ml (mean 1.85 ml; range 0.12-16.9 ml) for observer 1, 0.35 ml 
(mean 0.40 ml; range 0.12-2.2 ml) for observer 2 and  0.35 ml (mean 0.48 ml; range 
0.12-3.4 ml) for observer 3.  Imaging findings suggestive of deep myometrial invasion, 
cervical stromal invasion, and/or pelvic or para aortic lymph node metastases were 
recorded after the same criteria as in Paper I. Tumor volume was estimated based on 
the standard anatomical images with measurements of maximum tumor diameter in 
three orthogonal planes (x, y, and z) using the following equation (assuming a 
spherical tumor shape): Tumor volume = x × y × z / 2. 
 
  
 For Paper III, the maximum tumor diameters were measured in 3 orthogonal 
planes: anteroposterior (AP) and transverse (TV) diameters on axial CE T1-weighted 
oblique images (perpendicular to the long axis of the uterus) as well as craniocaudal 
(CC) diameters on sagittal T2-weighted images (Fig. 4). Tumor volume was then 
estimated based on these measurements of maximum tumor diameter in 3 orthogonal 
planes using the following equation: tumor volume = AP diameter × TV diameter × 
CC diameter/2. The staging parameters deep myometrial invasion, cervical stromal 
invasion and the presence of lymph node metastases were also recorded using the 
same criteria as described for Paper I and II.  
 For Paper I, II and III, a majority rating for the registered parameters was 
established by using the value given by the majority of the observers for categorical 
variables and the median value for continuous variables. For Paper I, in which there 
were four observers, an expert majority rating was established by applying the same 
method on the ratings of the three consultants. 
  
  
  A new dataset consisting of the majority ratings was computed for each paper, and 
this rating was used to explore the different parameters in relation to clinical and 
histological tumor characteristics.  
 The MRI readings were always preceded by a pilot study of five cases 
independently read by the participating observers, and recorded in the standardized 
form. Eventual disagreements could then be discussed to achieve a common 
understanding of the image reading criteria applied. The five pilot cases were always 
excluded from the final analyses. 
 
4.2.2 FDG-PET/CT reading 
A standard imaging report was generated by the responsible nuclear physician and 
radiologist and reported to the clinical team as part of the routine clinical diagnostic 
work-up. This imaging report was read and approved by a specialist in nuclear 
medicine and a radiologist subspecialized in the field of pelvic imaging as part of the 
standard reading set-up at our institution. 
After use for routine diagnosis, all images were deidentified, processed and 
reviewed retrospectively and independently by two physicians experienced in both 
nuclear medicine and radiology, on a Segami Oasis workstation (v. 1.9.4.2; Segami 
Corporation Columbia, MD, USA). Both readers had ~ four years’ experience with 
PET-CT prior to the study. They were blinded to clinical data and results of surgical 
staging, and reported imaging findings in a standardized form. This registration form 
(see appendix) included information on tumor avidity and uptake intensity as well as 
metabolic tumor volume. Information on presence of increased FDG uptake of the 
cervix (interpreted as cervical stroma invasion), in lymph nodes (interpreted as lymph 
node metastases) and at distant sites (interpreted as likely metastases), was also 
recorded. The depth of myometrial invasion based on FDG uptake was not registered, 
due to the low resolution of PET signals, perceived to preclude myometrial invasion 
assessment. 
The PET images were fused with both the diagnostic and the low-dose CT 
images on the Oasis workstation. All measurements were performed using the low-
dose fusion, whereas the diagnostic fusion was used for staging. For the measurements 
of metabolic tumor volume (MTV) and average standardized uptake value 
(SUVmean), voxels with SUV >2.5 were included in the volume of interest (VOI) 
(Fig.5). Total lesion glycolysis (TLG) in the tumor was also estimated using the 
following equation: TLG = SUVmean * MTV (103). For the statistical analyses of 
continuous variables, the mean of the two observers’ measurements was applied. To 
achieve a common understanding of the image reading criteria for assessing tumor 
avidity and uptake intensity as well as metabolic tumor volume, the two observers 
independently recorded five selected pilot cases in the registration form. 
Disagreements and different interpretations were discussed to reach a common 
understanding of the criteria applied. These five cases were then excluded from the 
cohort.

4.3 STATISTICAL METHODS 
Interobserver agreements were measured using exact Fleiss kappa (κ). Agreement 
beyond chance was interpreted as poor (κ ≤ 0.20), fair (κ = 00.21–0.40), moderate (κ = 
00.41–0.60), good (κ = 00.61–0.80) or very good (κ = 00.81–1.00). Intraclass 
correlation coefficient (ICC) was used to assess the consistency and reproducibility of 
ADC value measurements (Paper II), tumor size measurements (Paper III) and the 
quantitative PET/CT parameters (Paper IV), and minimal detectable change (MDC; 
1.96 × standard error of the mean × square root of 2) for the measured ADC values 
(Paper II) and the measured tumor diameters (Paper III) were also calculated. For the 
imaging findings of deep myometrial invasion, cervical stromal invasion and 
suspected lymph node metastases, the following analyses were performed:  
 
1. Sensitivity, specificity, accuracy, positive and negative predictive values (with 
binominal 95% CIs in Paper I), and number of false positive/negative findings 
were calculated for each observer, for the majority rating (Paper II and III), 
the expert majority (Paper I) and for the clinical report (Paper IV). 
2. Differences in sensitivity, specificity and accuracy between observers and the 
expert majority were collectively analyzed with Cochran’s exact Q test; if 
significant, McNemar’s test was used for pairwise analysis of the same, and the 
prevalence of imaging findings and surgical staging was compared using 
Cochran’s exact Q test (Paper I). 
 
Odds ratios for the presence of deep myometrial invasion, cervical stromal invasion 
and lymph node metastases at surgical staging were calculated using Fisher’s exact test 
for dichotomous variables and univariate logistic regression for continuous and 
categorical variables.  
 For the examinations of relationships between clinical histological tumor 
characteristics and imaging quantifications, univariate linear regression models (Paper 
II), Mann-Whitney U test, Jonckheere-Terpsta trend test (Paper III and IV), Kruskal-
Wallis H test, Χ2 test and binary logistic regression analysis (Paper III) and 
multivariate logistic regression analyses (Paper IV) were used. 
 Receiver operating characteristic (ROC) analyses were utilized to evaluate the 
diagnostic value of the different tumor quantifications in identifying important staging 
parameters. ROC analyses were also applied to determine the best cut-off values for 
ADC (Paper II), tumor size (Paper III) and MTV (Paper IV), by aiming for values 
achieving the best separation between groups by the Youden index. 
 Differences in time to recurrence or progression (Paper III) were assessed by 
the Mantel-Cox (log-rank) linear trend test. The Cox proportional hazards model was 
used to study effects on survival and univariate analyses using Kaplan-Meier was 
applied to explore the prognostic value of different tumor size categories. 
 In Paper III sample size was estimated by Χ2 test using software East4 2005 
(Cytel Software Corp). For all other analyses, SPSS 20.0-22.0 (Chicago, IL, USA) and 
STATA 12.1 (College Station, TX) were used. All reported P values were two-sided 






In Paper I, we evaluate the interobserver agreement among radiologists evaluating a 
cohort of 57 consecutive patients with histologically confirmed endometrial 
carcinoma, all prospectively included in a study of preoperative 1.5-T MRI. We report 
overall and pairwise agreement among four readers blinded to clinical information and 
results of surgical staging in the evaluation of three key features for risk assessment in 
endometrial carcinoma: deep myometrial invasion (tumor invading ≥ 50% of the 
myometrium), cervical stromal invasion and the presence of lymph node metastases. 
Overall agreement among all observers was moderate for cervical stroma invasion 
(κ=0.50 [95% CI 0.27–0.73]) and lymph node metastases (κ=0.56 [0.09–0.80]) and 
fair for deep myometrial invasion (κ=0.39 [0.26–0.55]). Sensitivity (specificity) values 
for the four observers were 72–92% (44–63%) for deep myometrial invasion, 38–63% 
(82–94%) for cervical stroma invasion and 25–38% (90–100%) for lymph node 
metastases. 
 
In Paper II, we explore possible correlations between tumor apparent diffusion 
coefficient (ADC), morphological tumor volume, and clinical and histological 
characteristics in 105 consecutive endometrial carcinoma patients and evaluate 
interobserver agreement for preoperative staging by MRI and for ADC measurements. 
Analyses of ADC values in relation to histomorphological characteristics and tumor 
volume showed that the mean tumor ADC was significantly lower in tumors with deep 
myometrial invasion (ADC = 0.75 × 10-3mm2/s) compared with tumors with 
superficial or no myometrial invasion (ADC = 0.85 × 10-3mm2/s; p < 0.001). ADC 
was negatively correlated to tumor size (p = 0.007). The interobserver agreement was 
fair (κ = 0.32) for depth of myometrial invasion, good for cervical stromal invasion (κ 
= 0.66), and moderate for lymph node metastases (κ = 0.54), and the interobserver 
variability for ADC value measurements was low (ICC = 0.60). 
 
In Paper III, we investigate the relation between preoperative tumor size based on 
MRI and the surgical pathological staging parameters (deep myometrial invasion, 
cervical stromal invasion and metastatic lymph nodes) in a cohort of 212 consecutive 
patients with histologically confirmed endometrial carcinoma. The overall aim is to 
assess the prognostic impact of tumor size in endometrial carcinomas, and we find that 
anteroposterior tumor diameter independently predicts deep myometrial invasion (P = 
0.001), whereas CC tumor diameter tends to independently predict lymph node 
metastases (P = 0.06). Based on ROC curves, the following tumor size cut-off values 
are identified: anteroposterior diameter greater than 2 cm predict deep myometrial 
invasion (unadjusted odds ratio [OR], 12.4; P < 0.001; adjusted OR, 6.7; P < 0.001) 
and CC diameter greater than 4 cm predict lymph node metastases (unadjusted OR, 
6.2; P < 0.001; adjusted OR, 4.9; P = 0.009). Large tumor size is associated with 
reduced progression/recurrence-free survival (P ≤ 0.005 for all size parameters), and 
CC diameter has an independent impact on survival (adjusted hazards ratio, 1.04; P = 
0.009). The interobserver variability for the different size measurements was also 
calculated, and proved very low (ICC 0.78-0.85). 
 
In Paper IV, we prospectively examine the diagnostic value of 18F-FDG-PET/CT for 
preoperative staging in endometrial carcinomas and possible correlations between 
18F-FDG-PET/CT specific imaging quantifications and clinical and histological 
characteristics in 129 consecutive endometrial carcinoma patients. Sensitivity 
(specificity) and accuracy of FDG-PET/CT for the detection of lymph node metastases 
are 77-85% (91-96%) and 89-93%, respectively. SUVmax, SUVmean, MTV and TLG 
are significantly related to deep myometrial invasion, presence of lymph node 
metastases and high histological grade (p<0.015 for all), and independently predict 
deep myometrial invasion (p<0.015) and lymph node metastases (p<0.025) after 
adjusting for preoperative histological risk (based on subtype and grade) in 
endometrial biopsies. Optimal cut-off values for MTV in predicting deep myometrial 
invasion (20 ml) and presence of lymph node metastases (30 ml), yield ORs of 7.8 





6.1 METHODOLOGICAL CONSIDERATIONS 
The patient cohort included in this thesis is population-based, as all patients have been 
consecutively recruited since the beginning in 2010. Exclusion criteria have been lack 
of suitability or adequacy of the patient, such as severe claustrophobia or dementia 
which have been the case in very few patients. Retrospectively, also patients with 
unconfirmed diagnosis and cases where the diagnosis was changed after surgery have 
been excluded. Finally, we excluded patients in whom the imaging performed was not 
interpretable due to artifacts or technical errors.  
 Even if Haukeland University Hospital serves a population of about one million 
inhabitants, the single institution design of these studies is a study limitation, and 
further studies including multiple centers is warranted to confirm that the current 
findings can be reproduced independent of institution size and location. In Paper I, the 
sample size is relatively small, in Paper II, III and IV; however, the sample sizes are 
larger. In all studies, however, the sample size seems satisfactory for the line of 
conclusions drawn. 
 In both Paper I and Paper III, the imaging protocols were based on the 
guidelines of the European Society of Urogenital Imaging and thus expected to be 
quite similar to those applied in most centers treating endometrial cancer patients. In 
Paper I, the choice of imaging protocols may have affected the staging accuracy and 
the interobserver agreement, and one may speculate that application of newer MRI 
techniques such as DWI and DCE imaging could improve these parameters, although 
this would call for an interobserver evaluation of these methods as well.  
 In addition to the interobserver variability which is crucial to examine in order 
to validate the clinical application of radiological examinations, intraobserver 
variability is another significant feature of radiological image reading. This has not 
been assessed in any of our studies, but is expected to be lower than the interobserver 
variability, thus probably on an acceptable level in our material. 
 For the DWI in Paper II, we acknowledge that an optimization of the protocol 
could have been favorable. We could have used at least two orthogonal planes instead 
of one and with more than two b-values in the ADC map. Our protocol is, however, 
similar to that reported in comparable studies at the time (62, 104). Also, the method 
for calculation of tumor volume in this study may be a limitation as it assumes a 
spherical tumor shape. Alternatively, we could have drawn a manual ROI on every 
single slice resulting in a perhaps more precise tumor volume. Assuming a spherical 
tumor shape seemed however more feasible in clinical practice, as the alternative 
would have been much more time consuming.  
For the size and location of the tumor ROIs measuring the ADC value in Paper 
II, there was no absolute standardization, giving rise to some variation between 
readers. Due to variable tumor size and shape, however, exact criteria for ROI size and 
placement were difficult to define. Still, we do not believe that varying ROI sizes and 
shapes have largely affected the results, as two of the readers measured very similar 
ROIs, and linear regression analysis showed that ROI size was not correlated to ADC 
value for any of the readers (p>0.05).  
 Finally, there is a certain limitation in the fact that the ROC analyses are 
conducted a posteriori in Paper II, III and IV. It may have been conceivable to 
prespecify a cut-off value by implementing a learning dataset including a smaller 
number of patients from the same patient population and achieve a priori cut-offs for 
utter validation (105). However, our patient cohort is presently considerably extended, 
and we plan to validate the proposed cut-off values in this larger, consecutive patient 
group. 
  
6.2 DISCUSSION OF RESULTS 
6.2.1 Inter-rater agreement 
Inter-rater variability is a crucial feature in evaluating the accuracy of a diagnostic test. 
In order to secure reproducibility, inherent subjectivity must be low, and concordance 
between measures high (106). In our studies we have observed various degrees of 
agreement between readers, both for image interpretations and quantifications. 
Diagnostic imaging suffer from a certain degree of variability since most images are 
read and interpreted by humans (in contrast to computer read imaging); yet many 
imaging techniques and diagnostic tests are implemented in the clinic before measures 
of intra- and interobserver variability has been thoroughly assessed (107).  
 In in Paper I we found modest agreement among four readers on preoperative 
staging of endometrial carcinomas by MRI, varying from fair (κ=0.39) for the 
presence of deep myometrial invasion to moderate (κ=0.50/0.56) for cervical stromal 
invasion and lymph node metastases, respectively. This study comprising 57 
endometrial carcinoma patients is to the best of our knowledge the largest and most 
comprehensive report on interobserver variability for pelvic MRI after implementing 
the revised FIGO 2009 system. Similar results for interobserver agreement were found 
in Paper II, comprising a larger patient cohort (n=105) and with readers having access 
to the b1000 DWI series and the corresponding ADC maps during the image 
interpretation. In Paper II the agreement between the three readers was fair (κ=0.32) 
for deep myometrial invasion, good (κ=0.66) for cervical stromal invasion and 
moderate (κ=0.54) for the presence of lymph node metastases. Interestingly, the 
agreement for these clinically relevant staging parameters was apparently not affected 
by the readers’ access to the b1000 DWI series and the corresponding ADC maps 
during the image interpretation, series that were not accessible during the reading of 
the images in Paper I. 
Previous studies of preoperative MRI staging of endometrial carcinomas 
include only two readers (108-110), and report good interobserver agreement on T2-
weighted imaging for deep myometrial invasion (κ=0.66/0.67 at 3.0 and 1.5 T, 
respectively), cervical stromal invasion (κ=0.77/0.76) and lymph node metastases 
(κ=0.64/0.74) (108), good to excellent agreement on 3.0 T T2-weighted imaging 
(κ=0.63), DCE T1-weighted imaging (κ=0.84) and fused DWI (κ=0.79) (109), and 
good to excellent agreement on 1.5 T T2-weighted imaging (κ=0.91) and DWI 
(κ=0.74) and moderate agreement on DCE T1-weighted imaging (κ=0.45) (110). 
Compared with these reported numbers, our figures for interobserver agreement seem 
to be in the lower range. There is no obvious explanation for this apparent lower 
agreement in our studies. We find that agreement is relatively similar among both 
experienced and less experienced readers, indicating that the duration of training in 
pelvic MRI (in this case non-standardized) does not have significant impact on the 
degree of interobserver variability. It is conceivable that a more standardized and 
dedicated training program could reduce the interobserver variability, but this remains 
unexplored so far. There are some differences between our protocol and those applied 
by in comparable studies; ours did not include dynamic contrast-enhanced series as 
used in two of the previous studies (109, 110), but this is not likely to have a large 
impact on the agreement as the equilibrium phase (with 2 min delay; used in our 
protocol) is regarded as the optimal phase for assessing deep myometrial invasion (54, 
111). 
 For the quantitative imaging parameters (ADC value in Paper II, 
diameters/volume in Paper III and SUVmax/mean, MTV and TLG in Paper IV), the 
interobserver variability was lower than for the staging parameters. ADC 
measurements have previously shown a high degree of interobserver reproducibility 
when applied in normal pancreatic tissue (112). Similarly, our interobserver agreement 
for these measurements was good with an ICC of 0.60. This result suggests that for the 
evaluation of the depth of myometrial invasion, tumor ADC measurements are less 
prone to subjective influence than the assessment based on conventional MRI, where 
the agreement was fair (κ=0.32).  In Paper III, the interobserver variability for 
different tumor size measurements at MRI was assessed, to our knowledge as the first 
study in the literature. Interobserver variability turned out to be very low, and 
interestingly, there was no striking difference related to the readers’ previous 
experience. Tumor size measurements thus seem to represent robust potential 
biomarkers for inclusion in future risk stratification models in endometrial cancer. For 
the quantitative parameters studied in Paper IV, the interobserver agreement was 
moderate for MTV (0.56) and TLG (0.57) and very good for SUVmax (0.98) and 
SUVmean (0.87). This difference is probably due to the subjective steps involved in 
the MTV measurement, where the size of the VOI is determined manually in three 
planes. The SUV measurements are more robust, as SUVmax only depends on the one 
single voxel with the highest value being included in the VOI. No previous studies of 
endometrial cancer have assessed the interobserver agreement for PET parameters, but 
other types of cancer have been examined, reporting ICC of 0.60-1.00 and 0.85-0.97 
for SUVmax and SUVmean, respectively (113-115), seemingly in line with our 
results. One study of interobserver variability in whole-body MTV measurements in 
small-cell lung cancer (116) found concordance correlation coefficients of 0.90 
(good); however, this is a study assessing the whole-body tumor burden, and thus not 
directly comparable to our study measuring the primary metabolic tumor volume only. 
Our observations and the literature taken together, it seems that the volume dependent 
parameters are less robust than the SUV measurements. However, the very similar 
ROC curves (117) for the different observers in our study, suggest that MTV may still 
represent a robust imaging biomarker for the prediction of deep myometrial invasion 
and the presence of lymph node metastases.  
 
6.2.2 Diagnostic performance of loco-regional staging 
 Improved preoperative imaging tools to enable tailoring of surgical and adjuvant 
therapies for endometrial carcinoma patients have long been highly warranted, 
especially to reduce the need for staging lymphadenectomy, which is currently 
frequently performed despite lack of documented survival benefit (2). MRI is presently 
the preferred imaging method for preoperative evaluation of endometrial carcinoma 
patients (1, 31, 56), but the method has some limitations (56, 118). In the present 
Paper I, the staging performance of MRI for deep myometrial invasion for all four 
observers was mostly within the lower range of what has been previously reported 
(sensitivity of 72-92% among the four readers), and with a lower specificity (44-63%). 
Recent literature reports 51-89% and 72-100%, respectively, for these staging criteria 
(54, 56, 59-61, 108, 118-125). One explanation for our lower specificity may be the 
tendency to overestimate the prevalence of deep myometrial invasion, a tendency also 
reported by others (110, 126). The study setting may also have contributed to over-
reading of abnormal findings, as opposed to the reading situation in an every-day 
clinical setting.  
 In Paper II, where the patient cohort was larger, and the three readers had 
access to the DWI series and the ADC map in addition to the conventional MRI, the 
sensitivity for prediction of deep myometrial invasion was lower,  (68-74%), but the 
specificity somewhat higher (56-93%) than in Paper I. One may speculate if the 
readers have changed their staging strategy after learning that they had a tendency to 
overstage deep myometrial invasion in Paper I. The staging performance may 
potentially also have been improved by adding at least two orthogonal planes in the 
DWI protocol and fused DW and T2/T1 CE imaging for the staging purposes. 
 For the important staging criterion of lymph node spread, the staging 
performance in Paper I was low with a sensitivity of 25-38%. Still, these numbers are 
comparable to what have been reported by others (17-80%) (54, 59, 60, 108, 120, 
127). In Paper II, the sensitivity had increased (38-46%), but must still be 
characterized as modest. We never aimed to perform a detailed comparison node by 
node of imaging findings and histopathological lymph node findings. All suspicious 
nodes (based on the size criterion of ≥ 10mm short-axis diameter (128) were, however, 
known to the surgeons preoperatively by the routine imaging report, and attempted 
removed and sent to histopathological evaluation. The use of additional malignancy 
criteria for lymph nodes (irregular contour, central necrosis, and increased short axis to 
long axis ratio) (128) may potentially have increased sensitivity in both studies, but 
would also have introduced an additional element of subjectivity in the evaluation, 
possibly decreasing the reproducibility and thus, the validity of the method. 
 In Paper IV, FDG-avidity was used to evaluate potential metastatic lymph 
nodes, and size was not taken into consideration, except for the understanding of FDG-
PET’s limited value in characterizing structures < 7mm (129). The sensitivity for 
detection of metastatic lymph nodes by FDG-PET/CT in Paper IV was 77-85% for 
the two readers and the clinical report. This is within the higher range compared to 
most previous studies reporting sensitivities of 60-83% (32, 33, 35, 71, 130). An 
interestingly high negative predictive value (NPV) of 97-98% confirms two previous 
reports finding NPV of 95% (71) and 96% (33), and indicates that FDG-PET/CT 
presently is the most promising method for ruling out the presence of lymph node 
metastases and need for a staging lymphadenectomy. This could be implemented in 
the decision-making and planning of surgery in order to avoid potentially harmful 
short and long- term side effects from unnecessary staging procedures. 
 For the staging criterion of cervical stromal invasion, none of our studies 
yielded high detection rates, Paper I reporting a sensitivity of 38-63%, Paper II; 44-
56% and Paper IV; 25-33%. A recent review of 12 studies reporting on the reliability 
of contemporary MRI in the assessment of high-risk features in endometrial 
carcinoma, including 1153 patients, (57) reported a pooled sensitivity of 57% for the 
detection of cervical stromal invasion, seemingly comparable to our results in Paper I 
and II. Comparable reports for the detection of cervical stromal invasion for FDG-
PET/CT seem to be lacking in the literature, thus we do not know if our sensitivity in 
Paper IV is lower than expected. Anyhow, it seems fair to conclude that FDG-
PET/CT is less accurate in the detection of cervical involvement from endometrial 
cancer than MRI. On the other hand, for stage II disease evidence from randomized 
trials for any survival benefit from radical hysterectomy compared to simple 
hysterectomy is missing, leaving no strong evidence that this distinction is critical for 
surgical therapy. The prognostic information will be obtained when assessing the 
hysterectomy specimen, allowing tailored adjuvant therapy for stage II disease 
nevertheless.     
 
6.2.3 Imaging quantifications 
Several risk models based on surgicopathological tumor features have been proposed 
in endometrial cancer (83, 131, 132), based on histologic grade, subtype and tumor 
extent, including gross tumor size. The limitation of these models is obviously the fact 
that the surgicopathological staging results are only available postoperatively, and 
cannot be used in a preoperative risk stratification aiming to tailor the extent of 
surgery. Advanced preoperative imaging grants the possibility to establish several 
tumor measurements for implementation in risk stratification models in order to 
individualize not only adjuvant treatment, but also primary surgery.   
In Paper II, the tumor ADC value in DWI was explored as a potential 
biomarker for tumor aggressiveness in endometrial carcinoma. We found that the 
tumor ADC value was significantly lower in tumors with deep myometrial invasion, 
and that tumor volume was negatively correlated to tumor ADC value. Low tumor 
ADC value reflects restricted diffusion of water molecules. Carcinomas are expected 
to have increased cellularity due to the abnormal growth pattern of malignant cells, 
leaving less extracellular space for water molecule diffusion. Two previous studies 
including cohorts of 48 (109) and 70 (133) patients contrast our finding of lower ADC 
value in tumors with deep myometrial invasion, however, the negative correlation 
between tumor ADC value and volume is supported by some previous studies (109, 
134), though not all (133). Tumor volume is an established indicator for aggressive 
disease in many cancer types (135), and a lower ADC value in large tumors may 
reflect an increased cellular density in a presumably faster growing tumor. As deep 
myometrial invasion is an established marker for aggressive disease in endometrial 
carcinomas (101), low tumor ADC values in both large and deeply infiltrating tumors 
go well with the current literature in the field. 
Paper III reported a significant predictive value of preoperative tumor size 
measurements based on MRI to identify deep myometrial invasion and lymph node 
metastases. We also found that survival was significantly influenced by tumor size, 
also after adjusting for preoperative risk profile based on the results of endometrial 
biopsy. All the measured tumor size parameters (all three orthogonal planes) predicted 
deep myometrial invasion, in accordance with the findings of Todo et al (136) who 
reported high volume indexes (defined as the product of maximum AP, TV and CC 
tumor diameters in MRI) to be associated with deep myometrial invasion. Unlike Todo 
et al, our study also explored the impact of the different size measurements when 
evaluated independently in a multivariate model including preoperative risk status 
based on endometrial biopsy. The AP diameter then proved to be the only size variable 
independently predicting deep myometrial invasion. The proposed cut-off of 2 cm for 
the AP diameter was achieved using ROC curves, and interestingly, this cut-off turned 
out to have comparable accuracy (sensitivity, specificity) to conventional MRI reading  
for the identification of deep myometrial invasion: 79% (66%, 86%) and 74% (70%, 
77%), respectively. AP measurement is a relatively simple approach compared to 
conventional MRI reading, and possibly easier attained, also for inexperienced readers. 
A macroscopic tumor diameter greater than 2 cm in hysterectomy specimens has been 
reported to independently predict lymph node metastases and survival (137), but this 
finding is not consistently confirmed in the literature (131, 138). Another report based 
on macroscopic gross inspection of the cut-up of the uterus, found that a maximum 
tumor dimension greater than 3.75 cm independently predicted deep myometrial 
invasion, distant recurrence and death (139). In our study, the CC diameter was almost 
unexceptionally the largest tumor diameter, so our cut-off of 4 cm seems to be in line 
with Chattopadhyay et al (139), even if tumor measurements on macroscopic fresh 
tissue is not directly comparable to tumor measurements on MRI, due to the 
potentially different planes of measurement and the differences in stretching and 
compression of tumor tissue ex vivo compared to in vivo. However, large tumor size 
as a predictor of increased metastatic potential and unfavorable prognosis in 
endometrial carcinomas seems to be broadly supported in the present literature (131, 
136-141). 
The significant impact of tumor size (specifically AP diameter>2 cm and CC 
diameter>4 cm both independently and combined) on progression/recurrence free 
survival lacks comparable data in current literature, but we suggest further exploration 
of these tumor size parameters in relation to other preoperative biomarkers such as 
p53, hormone receptor and DNA ploidy status in preoperative biopsies and functional 
imaging parameters from MRI or PET/CT, which also provide preoperative prognostic 
information (134, 142-145). 
Paper IV suggests MTV in FDG-PET/CT as a potential useful tool in 
preoperative risk stratification in endometrial carcinoma. The proposed cut-offs of 20 
ml for deep myometrial invasion and 30 ml for lymph node metastases interestingly 
improve sensitivity (specificity) of detection; 79% (68%) and 85% (76%) respectively; 
compared to the clinically established method based on assessment of histologic 
subtype and grade in preoperative biopsies, which in this cohort yielded sensitivity 
(specificity) of 47% (72%) for deep myometrial invasion and 85% (66%) for lymph 
node metastases. In line with this, MTV independently predicted deep myometrial 
invasion and lymph node metastases, after adjusting for the preoperative biopsy risk 
assessment in logistic regression analyses. These results support one recent study of 56 
endometrial carcinoma patients (69), that reports MTV and TLG as significant 
predictors of several clinicopathological characteristics and superior to SUVmax for 
stratification into high- and low-risk. Two other recent studies, both including cohorts 
of 76 endometrial carcinoma patients (71, 78), propose MTV as a promising predictor 
of lymph node metastases and poor outcome.  
An MTV cut-off value of 9.4 ml has been suggested in one prior study of 56 
patients (69), aiming to differentiate between high-risk and low-risk tumors (based on 
surgicopathological assessment). This dissimilar result may be explained by unlike 
definitions between high- and low-risk groups and the higher proportion of  patients 
with advanced FIGO stage in this smaller cohort of 56 patients. To our knowledge, 
Paper IV is the first study proposing cut-offs for MTV based on ROC curves 
predicting deep myometrial invasion and presence of lymph node metastases. 
All four parameters measured in the FDG-PET images (SUVmax, SUVmean, 
MTV and TLG) were independent predictors of deep myometrial invasion and lymph 
node metastases after adjusting for high-risk based on histological subtype and grade 
in preoperative uterine biopsies.  Previous studies have also assessed the prognostic 
value of SUVmax in cohorts of 101, 268 and 56, respectively (34, 69, 75), but none of 
these adjusted for the routinely applied methods for preoperative risk assessment. A 
recent review including 10 studies and 771 patients (70) concluded that SUVmax may 
aid in prediction of outcome, but that the value in preoperative risk stratification is 
limited, even if a statistically significant difference in SUVmax of high- and low-risk 
groups was present. SUVmean is less studied in the literature, but was associated with 
FIGO stage, histologic grade, lymphovascular space invasion and maximum tumor 
size (similar to SUVmax) in a study of FDG-PET/CT in 60 endometrial carcinoma 
patients (72). Our findings that MTV and TLG are associated with the depth of 
myometrial invasion and tumor invasion of the cervical stroma, are in line with three 
previous, smaller studies including cohorts of 76, 84 and 56 patients (69, 71, 146).
 When performing quantifications in PET tumor imaging, it is crucial to be 
aware of the partial volume effect (PVE) when tracer uptake in small tumors is 
measured, and when imaging quantification methods are used in clinical practice and 
research. PVE is the result of two distinct phenomena; the first is a three-dimensional 
image blurring introduced by the limited spatial resolution in PET images. This 
phenomenon causes a so-called “spill-over” between regions, and can make tracer 
uptake in a small structure look larger, but dimmer (147). The second phenomenon is 
the tissue fraction effect, referring to the fact that each voxel in the image usually 
consists of more than one type of tissue, and the uptake measured in the voxel is the 
mean of different signal intensities. This effect is especially present on the edges of 
tracer-positive structures, as the voxels here often consist of both avid tissue and 
background tissue, and is often referred to as “spill-out” (a well-known phenomenon 
also in CT and MR imaging). To counteract these effects in our FDG-PET/CT study, 
all imaging was obtained at the same PET/CT scanner with standardized acquisition, 
processing and analyses of imaging data. 
 
6.2.4 Incidental findings 
When introducing a new imaging modality in a cancer patient group, the cost-
effectiveness of the method is an issue of consideration. FDG-PET/CT is highly 
sensitive for detecting increased cellular metabolism, but the cause of increased 
metabolism is not always obvious and additional imaging work-up, blood tests, 
biopsies and clinical follow-up may be required.  
 In the population based patient cohort in Paper IV, four synchronous cancers 
were detected (one lung cancer, one breast cancer, one thyroid cancer and one B-cell 
lymphoma) all with potentially poorer prognosis than the primary endometrial cancer. 
Incidental findings have not been published for a cohort of endometrial carcinoma 
patients before, but the finding of synchronous cancers in FDG/PET-CT imaging is 
previously reported for other primary cancer types (148, 149), and the prevalence 
seems to be comparable. A systematic and thorough cost-benefit analysis of 
FDG/PET-CT has not been aimed for in this study, and would probably be difficult to 
attain in this mixed, casuistic group, but we may speculate that the four patients with 
synchronous cancers detected and treated with curative intent particularly benefitted 
from the scanning. Whether this benefit could be considered cost-effective, needs to be 
elucidated in more comprehensive studies. In 13 patients with incidental findings, 
however, no significant pathology was confirmed during additional work-up, 
illustrating that follow-up examinations often yield negative results also known from 





7. Conclusions  
Interobserver agreement and diagnostic accuracy are modest for standard MRI in the 
evaluation of depth of myometrial invasion, the presence of cervical stromal invasion 
and lymph node metastases in endometrial carcinomas. In a population-based cohort, 
standard MRI alone is suboptimal for preoperative staging purposes, and improved 
imaging methods, possibly combined with histological and molecular classifications of 
endometrial biopsies (43-45) are warranted for improved preoperative risk 
stratification and promotion of individualized surgery  (Paper I). 
 
Low tumor ADC value is associated with the presence of deep myometrial invasion, 
and the ADC value is negatively correlated to tumor volume in endometrial 
carcinomas. The interobserver agreement for ADC measurements is higher than that of 
preoperative staging by standard MRI with DWI. Measurement of tumor ADC values 
in endometrial carcinomas may contribute to the preoperative identification of high-
risk patients with deep myometrial invasion (Paper II).   
 
Preoperatively assessed tumor size by MRI predicts the presence of deep myometrial 
invasion, cervical stromal invasion and lymph node metastases and is a considerable 
prognostic factor in endometrial carcinomas. We propose cut-off values of 2 cm for 
AP diameter and 4 cm for CC diameter to be clinically useful by alarming the clinician 
of a potentially high-risk endometrial cancer.  The two tumor size measures, both 
individually and in combination, should be tested further in a prospective biomarker 
implementation study of preoperative risk stratification models in endometrial 
carcinomas (Paper III). 
 
FDG-PET/CT is a valuable imaging tool for the detection of lymph node metastases in 
endometrial carcinoma patients, and particularly precise in identifying patients with 
low likelihood of lymph node spread.   PET specific image quantification parameters 
all correlate positively with the presence of deep myometrial invasion and lymph node 
metastases. The proposed cut-off for MTV outperforms histologic subtyping and 
grading from endometrial biopsies which is currently used in clinical practice to 
preoperatively stratify patients into high- and low-risk groups (Paper IV). Thus, MTV 
is a promising biomarker for preoperative risk stratification in endometrial cancer. 
 
  
8. Future perspectives 
Some future perspectives have already been highlighted, such as the need for cost-
effectiveness studies of the implementation of new imaging tools like FDG-PET/CT 
(Incidental findings paragraph, 7.2.4). Analyses must, in addition to the cost/benefit of 
incidental findings, also consider the costs of imaging compared to the costs related to 
unnecessary and potentially harmful treatments and/or staging procedures. In the 
process of introducing new diagnostic tools, an evaluation of the existing diagnostic 
algorithm must be performed; including considerations regarding potential exclusion 
of currently employed diagnostic tests in the preoperative work-up.  
 The novel imaging biomarkers proposed in this thesis need to be consolidated in 
large, prospective study settings, where cut-offs are applied a priori for the cohort. 
Such validation will be crucial in order to safely apply the results in an algorithm for 
individualized treatment.  Furthermore, there is need for clinical implementation 
studies yielding long term outcome data, where risk stratification models are 
standardly applied. Another aspect worth considering regarding clinical 
implementation is the importance of robustness of the parameters. A future 
development of methods for automatic assessments of imaging parameters could 
potentially increase robustness by ruling out the subjective element of image 
interpretation, an issue of constant concern in all imaging based diagnostics.   
 The establishment of new imaging markers also gives an opportunity to relate 
these novel biomarkers to established biomarkers and create a diagnostic algorithm 
aiming to more accurately identify high-risk patients preoperatively and thereby tailor 
therapy coherently. In line with this, the tumor measurement cut-offs from Paper III 
will be included in the MoMaTEC2 trial as part of a risk stratification model. 
 Furthermore, it would be interesting to investigate the relation between tumor 
volumes measured on MRI (Paper III) and the metabolic tumor volumes measured on 
FDG-PET (Paper IV). We currently do not know how much the morphologic tumor 
volume contributes to the measured metabolic tumor volume, and further studies are 
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Objective: The aim of this study was to explore the relation between preoperative tumor
size based on magnetic resonance imaging (MRI) and the surgical pathologic staging pa-
rameters (deep myometrial invasion, cervical stroma invasion, and metastatic lymph nodes)
and to assess the prognostic impact of tumor size in endometrial carcinomas. Interobserver
variability for the different tumor size measurements was also assessed.
Methods/Materials: Preoperative pelvic MRI of 212 patients with histologically con-
firmed endometrial carcinomas was read independently by 3 radiologists. Maximum tumor
diameters were measured in 3 orthogonal planes (anteroposterior, transverse, and
craniocaudal planes [CC]), and tumor volumes were estimated. Tumor size was analyzed in
relation to surgical staging results and patient survival. The multivariate analyses were
adjusted for preoperative risk status based on endometrial biopsy. Intraclass correlation
coefficients and receiver operating characteristics curves for the different tumor measure-
ments were also calculated.
Results: Anteroposterior tumor diameter independently predicted deep myometrial inva-
sion (P G 0.001), whereas CC tumor diameter tended to independently predict lymph node
metastases (P = 0.06). Based on receiver operating characteristic curves, the following
tumor size cutoff values were identified: anteroposterior diameter greater than 2 cm pre-
dicted deep myometrial invasion (unadjusted odds ratio [OR], 12.4; P G 0.001; adjusted OR,
6.7; P G 0.001) and CC diameter greater than 4 cm predicted lymph node metastases
(unadjusted OR, 6.2; P G 0.001; adjusted OR, 4.9; P = 0.009). Large tumor size was as-
sociated with reduced progression/recurrence-free survival (P e 0.005 for all size
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parameters), and CC diameter had an independent impact on survival (adjusted hazards
ratio, 1.04; P = 0.009). The interobserver variability for the different size measurements was
very low (intraclass correlation coefficient, 0.78Y0.85).
Conclusions: Anteroposterior tumor diameter greater than 2 cm predicts deep myometrial
invasion, and CC tumor diameter greater than 4 cm predicts lymph node metastases. Tumor
size is a strong prognostic factor in endometrial carcinomas. Preoperative tumor mea-
surements based on MRI may potentially improve preoperative risk stratification models
and thus enable better tailored surgical treatment in endometrial cancer.
Key Words: Endometrial carcinoma, Tumor size, Magnetic resonance imaging,
Prognosis
Received October 24, 2014, and in revised form November 9, 2014.
Accepted for publication December 8, 2014.
(Int J Gynecol Cancer 2015;25: 459Y466)
Endometrial cancer is the most common gynecologic ma-lignancy in industrialized countries, and the incidence is
increasing.1 Surgical treatment is planned based on preop-
erative assessment of histological subtype, grade, and depth
of myometrial invasion. Surgical International Federation of
Gynecology and Obstetrics (FIGO) stage is documented to be
the strongest prognostic factor in endometrial carcinoma, thus
guiding adjuvant therapy in addition to the assessment of his-
tologic subtype and grade in the hysterectomy specimen.1Y3
Magnetic resonance imaging (MRI) has long been con-
sidered the diagnostic imaging method of choice for preoper-
ative staging of endometrial carcinomas.4Y6 The presence of
deepmyometrial invasion and cervical stroma invasion could be
visualized, and enlarged lymph nodes could be detected.
However, conventional pelvicMRIhas reportedly limitations in
accuracy in the detection of the staging parameters, in particular
for detecting lymph node metastases.6,7 Interobserver variation
between radiologists for all staging parameters also represents a
source of inaccuracy.8
As opposed to the cervical cancer FIGO staging system,6
FIGO staging for endometrial cancers does not include tumor
size measurements. Nevertheless, large macroscopic tumor
size, assessed in the hysterectomy specimen, has long been
known to predict lymph node metastasis and poor survival in
patients with endometrial carcinomas.9Y13 Recent publications
support that tumor volume based on preoperativeMRI predicts
lymph node metastases and has prognostic impact in endo-
metrial cancer.14,15 However, the reproducibility of MRI-based
tumor measurements has, to our knowledge, not yet been ex-
plored. Furthermore, the optimal cutoff value for risk assess-
ment based on tumor size is not yet defined.
The primary objective of this study was to explore the
relationship between different preoperative tumor size mea-
surements using MRI and the surgical pathologic staging
parameters deep myometrial invasion, cervical stroma inva-
sion, and metastatic lymph nodes in endometrial carcinoma
patients. The secondary objectives were to assess the inter-
observer variability for the different tumor measurements and
to explore the value of these preoperative tumor size mea-
surements to identify patients with poor outcome.
MATERIALS AND METHODS
Patient Series, Study Setting,
and Clinical Outcome
This prospective study was conducted under institu-
tional review boardYapproved protocols with informed con-
sent from all patients. From April 2009 to November 2013,
preoperative pelvic MRI was performed in 212 patients in
whom the diagnosis of endometrial carcinoma was histo-
logically verified at surgical staging. All patients were diag-
nosed and treated at the same university hospital serving a
population of ~1 million inhabitants.
Follow-up data regarding recurrence, progression, and
survival have been collected from patient records and from
correspondence with the responsible primary physicians or
gynecologists. The date of the last follow-upwas July 2014, and
themean (range) follow-up for survivorswas25 (0Y58)months.
Histological Diagnosis
All patients were surgically staged according to the 2009
FIGO staging criteria.2 The responsible surgeon decided the
extent of sampling, balancing preoperatively known histologic
risk factors and the patient’s comorbidity. The patient group
without lymph node sampling is typically older with more
myometrial invasion, otherwise not different from the sampled
group.16 Surgical specimens were sectioned along the longi-
tudinal plane of the uterus, and myometrial invasion and cer-
vical stromal invasion were estimated grossly and confirmed
microscopically according to standard procedures.17 Routine
histopathology reports were generated without knowledge of
preoperative MRI findings. The pathologists documented
number and size of metastatic lymph nodes.
MRI Protocol
Contrast-enhanced (CE)MRI was performed on a 1.5-T
SiemensAvantoRunningSyngoMRB17 (Erlangen,Germany)
using a 6-channel body coil8 in accordance with the guidelines
of European Society of Urogenital Imaging.5 Themean (range)
interval between MRI examination and surgical staging was
11.3 (0Y98) days.
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Data Analysis
All images were deidentified and read independently by
3 observers who were blinded for tumor stage, histological
diagnosis, and patient outcome. Observer 1 and 2 are con-
sultants with more than 10 years of experience with pelvic
MRI. Observer 3 included 2 junior radiologists (both having
more than 4 years of experience with pelvic MRI); one read
the first 105 MRI examinations, and the other read the fol-
lowing 111 examinations.
All observers reported imaging findings on a stan-
dardized form. Presence of deep myometrial invasion (tumor
invading half or more of the myometrial wall), cervical stroma
invasion (disruption of the low-signal intensity cervical
stroma on T2-weighted images), and enlarged pelvic or para-
aortic lymph nodes (largest short-axis diameter 910mm)were
recorded. Maximum tumor diameters were measured in 3
orthogonal planes: anteroposterior (AP) and transverse (TV)
diameters on axial CE T1-weighted oblique images (per-
pendicular to the long axis of the uterus) as well as
craniocaudal (CC) diameters on sagittal T2-weighted images
(Fig. 1). Tumor volume was then estimated based on these
measurements of maximum tumor diameter in 3 orthogonal
planes using the following equation: tumor volume = AP
diameter  TV diameter  CC diameter/2.
To establish the overall imaging findings based on the
recordings by all 3 observers, we also computed a new data set
(‘‘consensus reading’’) in which the value given by the ma-
jority of the observers was recorded for categorical variables,
and the median value was recorded for continuous variables.
Statistical Analysis
Estimation of sample size was done by W2 test using
software East4 2005 (Cytel Software Corp). To achieve 90%
power of detecting a 20% higher occurrence of positive
markers in patients with metastatic lymph nodes (5% vs 25%)
at a 5% significance level, 101 patients were needed for in-
clusion, defining the minimum number of patients to be in-
cluded in theMRI study. To reach 90% power detecting a 30%
difference in 5-year survival (90% for patients with markers
within reference range vs 60% with pathologic markers) at a
5% level of significance, 65 patients were needed, assuming a
positive to negative ratio of the markers of 1:3.
Clinical and histopathology staging parameters were
analyzed in relation to tumor size measurements using Mann-
Whitney U test, Kruskal-Wallis H test, Jonckheere-Terpsta
trend test, W2 test, and binary logistic regression analysis.
Intraclass correlation coefficient was used to assess the
consistency and reproducibility of tumor size measurements,
and minimal detectable change (1.96  standard error of the
mean square root of 2) for the measured diameters was also
calculated.
Receiver operating characteristic (ROC) analysis was
performed to evaluate the diagnostic value of the different
tumor size measurements in identifying deep myometrial
invasion, cervical stroma invasion, and lymph node metas-
tases. The optimal cutoff values (rounded to centimeters) were
determined for which the best separation in Youden index
between groups was achieved.
Differences in time to recurrence (for patients consid-
ered cured by primary treatment) or progression (for patients
known to have residual disease after primary treatment) were
assessed by the Mantel-Cox (log-rank) linear trend test. The
Cox proportional hazards model was used to study the effect
on survival of continuous variables. The prognostic value of
different tumor size categories was explored with univariate
analyses using Kaplan-Meier, and groups with similar sur-
vival were merged. McNemar test was used for pairwise
analysis for differences in sensitivity, specificity, and accu-
racy. The data were analyzed using SPSS 22.0 (Chicago, IL)
and Stata 12.1 (College Station, TX). All reported P values
were 2-sided and considered to indicate statistical signifi-
cance when less than 0.05.
RESULTS
Patients
The median (mean) patient age in the study sample
(n = 212) was 66 (66) years (range, 32-93), and 91% (193/212)
of the patients were postmenopausal. Applying the FIGO
2009 staging criteria, 55% (116/212) were stage IA (G50%
FIGURE 1. Axial oblique CE T1-weighted image (A) and sagittal T2-weighted image (B) for measurements of
maximum tumor diameters in 3 orthogonal planes. AP and maximum TV diameters were measured on the axial
oblique image (A), whereas CC diameters were measured on the sagittal image (B).
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myometrial invasion), 23% (48/212) stage IB (Q50% myo-
metrial invasion), 11% (23/212) stage II (cervical stroma
invasion), 11% (24/212) stage III (local or regional tumor
spread), and 0% (1/212) stage IV. The histological subtype
was endometrioid in 81% (171/212) of which 50% (86/171)
were grade 1, 29% (50/171) grade 2, and 17% (29/171) grade
3; whereas 4% (6/171) were ungraded. Clear cell histology
was detected in 3% (6/212), serous in 10% (21/212), carci-
nosarcoma in 4% (9/212), and undifferentiated in 2% (5/212).
Metastatic lymph nodes were more frequent in patients with
deep myometrial invasion, cervical stroma invasion, high his-
tologic grade, aneuploidy, and body mass index (BMI) greater
than 25 (Table 1).
All patientswere primarily treatedwith hysterectomy and
bilateral salpingo-oophorectomy. Pelvic lymph node sampling
was performed in 85% (181/212) as part of the routine surgical
staging procedure. Adjuvant therapy was given to 33% (70/
212), chemotherapy in 28% (59/212), pelvic radiation in 5%
(10/212), and hormonal treatment in 0% (1/212).
Tumor Size Is Correlated to
Surgicopathologic Findings
The mean (median, range) preoperative tumor di-
ameters were 28 (26, 0Y113) mm for axial TV diameter, 18
(16, 0Y77) mm for axial AP diameter, and 35 (31, 0Y102) mm
for sagittal CC diameter. The mean (median, range) estimated
tumor volume was 19 (6, 0Y444) mL. Tumor volume was
significantly higher in patients with deep myometrial inva-
sion, cervical stroma invasion, and lymph node metastases at
surgical staging and in patients with aneuploidy and high
histologic grade (Table 2).
Tumor measurements in the 3 orthogonal planes and
tumor volume did all predict the presence of deep myometrial
invasion at surgical staging (unadjusted odds ratios [ORs],
1.06Y1.13; P G 0.001 for all); however, AP tumor diameter
was the only size variable independently predicting deep
myometrial invasion (adjusted OR, 1.14; P G 0.001).
Craniocaudal tumor diameter was the only variable predicting
cervical stroma invasion (adjusted OR, 1.04; P = 0.008).
Although all size parameters predicted lymph node metas-
tases in the univariate analyses (unadjusted ORs, 1.02Y1.05;
P e 0.004 for all), only CC tumor diameter tended to inde-
pendently predict lymph node metastases (adjusted OR, 1.04;
P = 0.06).
Receiver operator characteristic curves for the different
size parameters in the prediction of deep myometrial invasion
(Fig. 2A), cervical stroma invasion (Fig. 2B), and lymph node
metastases (Fig. 2C) showed that AP diameter had the highest
area under the curve (AUC, 0.82) for deepmyometrial invasion,
whereas CC diameter had the highest AUC for cervical stroma
invasion (AUC, 0.66) and for lymph node metastases (AUC,
0.76). Based on these ROC curves, the following cutoff values
were identified: AP tumor diameter greater than 2 cm predicts
deep myometrial invasion yielding sensitivity/specificity of
66%/86% and an OR of 12.4, and CC tumor diameter greater
than 4 cm predicts lymph node metastases yielding sensitivity/
specificity of 70%/73% and an OR of 6.2, whereas CC tumor
diameter greater than 3 cm tends to predict cervical stroma
invasion yielding sensitivity/specificity of 66%/51% and an
TABLE 1. Clinical characteristics and MRI findings in
relation to the presence of metastatic lymph nodes at




n = 20 n = 161
n (%) n (%)
Low-risk group† 72 0 (0) 72 (46) G0.001
Intermediate-risk group† 51 10 (50) 41 (26)
High-risk group† 54 10 (50) 44 (28)
Myometrial invasion G 0.001
G50% 109 4 (20) 105 (65)
Q50% 72 16 (80) 56 (35)
Cervical stroma invasion 0.001
Yes 27 8 (40) 19 (12)
No 154 12 (60) 142 (88)
Histologic subtype 0.14
Endometrioid 141 13 (65) 128 (80)




Grade 1 70 2 (15) 68 (55)
Grade 2 42 5 (38) 37 (30)
Grade 3 25 6 (46) 19 (15)
Ploidy 0.014
Diploid 77 6 (50) 71 (82)
Aneuploid 22 6 (50) 16 (18)
Age, y 0.10
G66 95 7 (35) 88 (54)
Q66 86 13 (65) 73 (45)
BMI 0.03
G25 66 3 (15) 63 (40)
Q25 113 17 (85) 96 (60)
Tumor size at MRI G0.001
AP e2 cm and/or
CC e4 cm
136 8 (40) 128 (80)




Enlarged lymph nodes 13 9 (45) 4 (2)
Normal lymph nodes 168 11 (55) 157 (98)
Significant P values are presented in boldface.
*W2 Test.
†Risk groups defined in European Society for Medical Oncology
guidelines26: low risk, endometrioid grade 1/2 with myometrial inva-
sion G50%; intermediate risk, endometrioid grade 1/2withmyometrial
invasion Q50% or endometrioid grade 3 with myometrial invasion G
50%; high risk, endometrioid grade 3 with myometrial invasion Q50%
or nonendometrioid histology
LN+, patients with lymph nodes metastases at surgical staging;
LNj, patients without lymph node metastases at surgical staging.
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OR of 2.0 (Table 3). When adjusting for risk status based on
preoperative endometrial biopsy and for conventional imaging
findings (consensus reading) suggesting deep myometrial
invasion, cervical stroma invasion, and lymph node metasta-
ses, respectively, AP diameter greater than 2 cm independently
predicted deep myometrial invasion (adjusted OR, 6.7), and
CC diameter greater than 4 cm independently predicted lymph
node metastases (adjusted OR, 4.9), whereas CC diameter
greater than 3 cm did not predict cervical stroma invasion
(Table 3).
Tumor Size Predicts Progression/
Recurrence-Free Survival
The 3 tumor diameter measurements and tumor volume
did all predict progression/recurrence-free survival (P e 0.01
for all size parameters) in endometrial carcinoma patients. In a
multivariate analysis including all size parameters and pre-
operative risk status based on endometrial biopsy, only CC
tumor diameter had an independent impact on survival (Table 4,
SupplementalDigital Content, http://links.lww.com/IGC/A270).
When stratifying patient groups according to the proposed
cutoff values for size variables defined by the ROC analyses,
patients with AP tumor diameter greater than 2 cm and patients
with CC tumor diameter greater than 4 cm had significantly
reduced progression/recurrence-free survival (P e 0.03 for
both; Figs. 3A, B). Combining these 2 size criteria yielded
similar survival curves among patients with both or 1 size
criterion below the cutoff values (the 2 survival curves are thus
merged in Fig. 3C), whereas patients with both AP tumor di-
ameter greater than 2 cm and CC tumor diameter greater than
4 cm had significantly reduced progression/recurrence-free
survival (P = 0.004; Fig. 3C).
Interobserver Variability for Tumor
Measurements
The interobserver variability for tumor diameter
measurements by the 3 observers was low with intraclass
correlation coefficients of 0.78 to 0.85 and minimum de-
tectable change of 14 to 26 mm for the different tumor di-
ameter measurements (Table 5, Supplemental Digital Content,
http://links.lww.com/IGC/A270). Furthermore, the AUCvalues
of the ROC curves for prediction of deep myometrial invasion,
cervical stroma invasion, and lymph node metastases were not
significantly different between observers (Figs. 2D-F).
DISCUSSION
In this large population-based study, we demonstrate a
significant predictive value of preoperative tumor size mea-
surements based on MRI to identify deep myometrial invasion
and lymph node metastases. Furthermore, tumor size had a
significant independent impact on survival alsowhen adjusting
for preoperative risk status based on endometrial biopsy. Based
on the present study, we propose a riskmodelwith cutoff values
of AP tumor diameter greater than 2 cm indicating high risk for
deep myometrial invasion and CC tumor diameter greater than
4 cm indicating high risk for lymph node metastases. Having
established that the interobserver variability for these different
tumor measurements at MRI was very low, we infer that these
preoperative tumor measurements with corresponding cutoff
values may represent robust biomarkers aiding in the preop-
erative risk stratification and in planning of tailored surgical
treatment in endometrial cancer patients.
Presence of deep myometrial invasion in hysterectomy
specimen at surgicopathological staging is associated with an
increased risk of lymph node metastases, tumor recurrence,
and distant relapse in endometrial carcinoma patients.3,18 We
found that all size parameters predicted deep myometrial
invasion, which is in accordance with the findings of Todo
et al14 reporting high volume indexes (defined as the product
TABLE 2. Tumor volume in relation to clinical and







G50% 132 7.4 (5.2Y9.7)
Q50% 80 37.5 (23.4Y51.6)
Cervical stroma invasion 0.049
Yes 32 33.7 (5.2Y62.2)
No 180 16.1 (11.4Y20.8)
Lymph node metastases G0.004
Yes 20 62.7 (12.0Y113.5)
No 161 13.9 (10.2Y17.6)
Histologic subtype 0.27
Endometrioid 171 13.4 (10.2Y16.6)
Clear cell 6 20.6 (0.0Y50.4)
Serous 21 21.0 (4.9Y37.1)
Carcinosarcoma 9 65.5 (0.0Y135.8)




Grade 1 86 8.9 (5.6Y12.1)
Grade 2 50 14.7 (9.4Y19.9)
Grade 3 29 26.5 (13.2Y39.8)
Ploidy 0.015
Diploid 91 24.7 (12.8Y36.7)
Aneuploid 23 41.1 (21.4Y60.7)
Age, y 0.21
G66 106 15.6 (7.0Y24.3)
Q66 106 22.0 (14.2Y29.8)
BMI 0.38
G25 74 15.1 (9.1Y21.1)
Q25 134 20.9 (12.4Y29.4)
Significant P values are presented in boldface.
*Mann-WhitneyU test for 2 categories and Kruskal-Wallis H test
or Jonckheere-Terpsta trend test for multiple categories.
CI, confidence interval.
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TABLE 3. Sensitivity, specificity, LR+, LRj, and OR for the prediction of deep myometrial invasion
(by AP tumor diameter 92 cm), cervical stroma invasion (by CC tumor diameter 93 cm), and lymph node
metastases (by CC diameter 94 cm) using surgical staging as the criterion standard
AP Tumor Diameter
92 cm and Deep
Myometrial Invasion
CC Tumor Diameter
93 cm and Cervical
Stroma Invasion
CC Tumor Diameter
94 cm and Lymph
Node Metastases
Sensitivity, % (positive/total no. patients) 66 (53/80) 66 (21/32) 70 (14/20)
Specificity, % (positive/total no. patients) 86 (114/132) 51 (91/180) 73 (117/161)
LR+ 4.9 1.5 2.6
LRj 0.39 0.68 0.41
Unadjusted and adjusted* OR (95% CI);
P value† for deep myometrial invasion/cervical
stroma invasion/lymph node metastases based
on size cutoff values
12.4 (6.3Y24.5) 2.0 (0.9Y4.3) 6.2 (2.2Y17.2)
P G 0.001 P = 0.10 P G 0.001
6.7 (3.1Y14.4) 1.1 (0.4Y2.7) 4.9 (1.5Y15.8)
P G 0.001 P = 0.85 P = 0.009
*Adjusted for risk status based on preoperative endometrial biopsy and conventional imaging findings (consensus reading) suggesting
deep myometrial invasion, cervical stroma invasion, and lymph node metastases, respectively.
†Binary logistic regression analysis.
LR+, likelihood ratio for positive results: LR+ = sensitivity/(1 j specificity); LRj, likelihood ratio for negative results: LRj =
(1 j sensitivity)/specificity.
FIGURE 2. Receiver operator characteristic curves for the various tumor size measurements for identification of (A)
deep myometrial invasion, (B) cervical stroma invasion, and (C) lymph node metastases and ROC curves for the
different observers for (D) AP diameter to predict deep myometrial invasion, (E) CC diameter to predict cervical
stroma invasion, and (F) CC diameter to predict lymph node metastases in patients with endometrial carcinoma.
P values refer to the test of equal AUC values across tumor measurements.
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of maximum AP, TV, and CC tumor diameters at MRI) to be
associated with deep myometrial invasion. As opposed to
Todo et al,14 we have also explored the independent impact of
the different size variables in a multivariate model including
preoperative risk status based on endometrial biopsy. Inter-
estingly, AP diameter, which had the largest AUC (Fig. 2A),
proved to be the only size variable independently predicting
deep myometrial invasion.
Based on the ROC curve, the optimal cutoff value for
prediction of deep myometrial invasion was AP diameter
greater than 2 cm, and AP diameter greater than 2 cm inde-
pendently predicted deep myometrial invasion even when
adjusting for conventional imaging findings (consensus
reading) suggesting the same. Interestingly, we found that
AP diameter greater than 2 cm and MRI indicating deep
myometrial invasion had comparable accuracy (sensitivity,
specificity) for identification of deep myometrial invasion at
surgical staging: 79% (66%, 86%) and 74% (70%, 77%),
respectively, however, with significantly better specificity for
AP diameter greater than 2 cm (86% vs 77%; P = 0.015,
McNemar test). Thus, this relatively simple approach of
measuring AP tumor diameter yields a diagnostic perfor-
mance similar to or slightly better than conventional reading
for prediction of deep myometrial invasion.
Several surgicopathological risk models for prediction
of lymph node metastases have been proposed in endometrial
cancer based on histologic grade, subtype, and tumor ex-
tent,10,19,20 among which 1 model includes tumor greater than
2 cm based on the gross inspection of hysterectomy speci-
men.10 These models are, however, limited by the fact that
they rely on surgicopathological staging results, which are per
definition not available preoperatively.
Tumor diameter greater than 2 cm in macroscopic fresh
tissue has been reported to independently predict lymph node
metastases and survival9; however, the independent impact on
survival of tumor size greater than 2 cm has not been consis-
tently reproduced in the literature.10,13 Based on macroscopic
gross inspection of the cut-up of the uterus, maximum tumor
dimension greater than 3.75 cm was recently reported an in-
dependent predictor of deep myometrial invasion, distant re-
currence, and death.11 Because CC diameter was almost
uniformly the largest tumor diameter in our study, our cutoff
value for CC diameter greater than 4 cm seems to be in linewith
the proposed cutoff value of 3.75 cm. Direct comparison be-
tween tumor diameter measurements in macroscopic fresh tis-
sue and preoperatively based on MRI is, however, difficult due
to the differences in planes eligible for tumormeasurements and
the potential distortion and compression of tumor tissue in vivo
compared with ex vivo. Thus, the optimal cutoff values for
tumor size are not necessarily transferable from in vivo MRI-
based assessment to the ex vivo gross section-based tumor
measurements. Still, the metastatic potential and unfavorable
prognostic impact of large tumor size in endometrial carcinomas
is consistently supported by both invivo and ex vivo studies.9Y15
We found that the MRI-based parameters AP tumor
diameter greater than 2 cm and CC tumor diameter greater
than 4 cm both alone and combined are strongly associated
with reduced progression/recurrence-free survival in endo-
metrial carcinomas (Fig. 3). These tumor size parameters
should in the future also be evaluated in relation to other
preoperative biomarkers such as p53, hormone receptor, and
DNA ploidy status in preoperative biopsies, prognostic
markers assessed in blood samples,21 and on functional im-
aging by MRI or PET/CT, which have been shown to yield
prognostic information.16,22Y25
For all risk stratification models, high accuracy and
reproducibility of the variables included in the model are
essential. To our knowledge, this is the first study assessing
the interobserver variability for the different tumor size
measurements at MRI in endometrial cancer. Interestingly, we
found that tumor size was measured with very low inter-
observer variability and with no striking difference related to
the readers’ previous experience. Thus, tumor size measure-
ments seem to represent robust biomarkers that are promising
for potential inclusion in future risk stratification models in
endometrial cancer.
FIGURE 3. Kaplan-Meier survival curves depicting progression/recurrence-free survival according to (A) maximal
AP tumor diameter (e2 vs 92 cm), (B) maximal CC tumor diameter (e4 vs 94 cm), and (C) a combination of AP
and CC tumor diameters (AP e2 cm and/or CC e4 cm vs AP 92 cm and CC 94 cm). P values refer to the log-rank
test for equality of survival distribution.
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This study has some limitations. First, the study was
conducted in a single institution using a standardized imaging
protocol. Thus, the potential impact of various imaging pro-
tocols on MRI-based tumor size measurements has not been
assessed. However, our imaging protocol is based on the
guidelines of the European Society of Urogenital Imaging and is
thus expected to be quite similar to those applied at most centers
treating endometrial cancer patients. Second, intraobserver
variability was not assessed in this study. This is, however,
expected to be lower than the observed interobserver variability,
which was very low in this study, and the intraobserver vari-
ability is thus expected to be almost negligible.
In summary, tumor size assessed preoperatively byMRI
predicts the presence of deep myometrial invasion and lymph
node metastases and is a strong prognostic factor in endo-
metrial carcinoma. Based on our findings, we propose cutoff
values greater than 2 cm AP tumor diameter for predicting
deep myometrial invasion and greater than 4 cm CC tumor
diameter for predicting lymph node metastases, as well as
poor survival for the combination of greater than 2 cmAP and
greater than 4 cm CC tumor diameter. Preoperative tumor
measurements at MRI may thus provide clinically relevant
biomarkers for future risk stratification models guiding tai-
lored surgical treatment in endometrial cancer.
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